Ubiquitin, SUMO and Nedd8 as therapeutic targets in cancer

Authors:

Pierre Gâtel, Marc Piechaczyk and Guillaume Bossis

Affiliations:

Equipe Labellisée Ligue Contre le Cancer, Institut de Génétique Moléculaire de Montpellier,
University of Montpellier, CNRS, Montpellier, France

Correspondence to:

guillaume.bossis@igmm.cnrs.fr

Phone: 0033434359671

Fax: 0033434359634

Conflict of interest:

The authors declare no conflict of interest

Abstract

Ubiquitin defines a family of approximately 20 peptidic post-translational modifiers collectively called the Ubiquitin-like (UbLs). They are conjugated to thousands of proteins, modifying their function and fate in many ways. Dysregulation of these modifications has been implicated in a variety of pathologies, in particular cancer. Ubiquitin, SUMO (-1 to -3) and Nedd8 are the best-characterized UbLs. They have been involved in the regulation of the activity and/or the stability of diverse components of various oncogenic or tumor suppressor pathways. Moreover, the dysregulation of enzymes responsible for their conjugation/deconjugation has also been associated with tumorigenesis and cancer resistance to therapies. The UbL system therefore constitutes an attractive target for developing novel anticancer therapeutic strategies. Here, we review the roles and dysregulations of Ubiquitin-, SUMO- and Nedd8 pathways in tumorigenesis, as well as recent advances in the identification of small molecules targeting their conjugating machineries for potential application in the fight against cancer.

Introduction

Ubiquitin is the founding member of a polypeptide family of approximately 20 protein post-translational modifiers [1]. For the sake of simplicity, these, together with Ubiquitin, will be called the Ubiquitin-likes, or UbLs, hereafter. Among them, Ubiquitin, Nedd8 and the 3 members of the SUMO family (SUMO-1 to -3) are at the heart of this review.

UbLs are small globular polypeptides of 8 to 12 kDa. They share low sequence similarity but high structural identity with one α -helix and five β -sheets (β -grasp fold) followed by a C-terminal tail [2]. In most cases, they are covalently conjugated to proteins via formation of an isopeptide bond between their C-terminal glycine and the ε -NH₂ group of lysines from substrates. Nevertheless, other, quantitatively minor, conjugations of Ubiquitin to other amino acid residues or at the N-terminus of proteins have been described.

The mechanisms of conjugation are very similar amongst the UbLs even though each one of them is transferred to protein substrates using specific sets of enzymes. Yet, certain of these enzymes can intervene in the conjugation of more than one UbL type under certain conditions (Table 1). As UbL conjugation/deconjugation processes have been described extensively in a number of reviews [3, 4], they will only be addressed briefly below. UbLs are first activated by UbL-activating enzymes called E1s. These use ATP to form a thioester bond between the UbL C-terminal glycine and their catalytic cysteine. The C-terminal glycine is then *trans*-thiolated, allowing the UbL to be transferred onto the catalytic cysteine of UbL-conjugating enzymes called E2s. Although E1s and E2s can, in some cases, be sufficient to conjugate certain UbLs on target proteins, they most often require a third factor called E3 [5, 6]. More than 600 E3s have been proposed for Ubiquitin, but much less for the other UbLs. Certain E3s can be full-blown enzymes. This is the case of the E3 Ubiquitin ligases from the HECT family, which harbor catalytic cysteines forming thioester bonds with the Ubiquitin C-terminal glycine before transfer of Ubiquitin onto protein substrates. However, in most cases, E3s function as mere adaptors between E2s and substrates to confer reaction selectivity. Certain UbLs can be conjugated to themselves via the formation of isopeptide bonds between their C-terminal glycines and certain of their own lysines. This is especially true for ubiquitin, which can form chains involving each one of its seven lysines (K6, K11, K27, K29, K33, K48, K63). These chains can be homotypic or heterotypic due to the multiplicity of conjugatable lysines on Ubiquitin [7]. Mixed chains between different UbLs can also be formed. The best-known ones are those between Ubiquitin and SUMO or Nedd8 [8]. Importantly, UbL conjugation is reversible and highly dynamic with

most substrates being constantly modified and demodified. Deconjugation is carried out by isopeptidases, which cleave the isopeptide bonds between UbLs and target lysines. This allows UbLs, which are highly stable polypeptides, to be recycled and re-conjugated to other proteins. Some isopeptidases are also involved in the proteolytic maturation of UbLs, which are synthesized in the form of precursors displaying extra amino-acids at their C-termini. Similar to E3s, isopeptidases show substrate specificity or, at least, preference for particular chain linkages [9]. Concerning the SUMO pathway, deSUMOylases, such as SENP6 and SENP7, preferentially cleave SUMO-2 chains, whilst others, such as SENP-1 and SENP-2, rather deconjugate SUMO bound to target proteins [10]. Some deSUMOylases such as SENP-3, SENP-5 and USPL1 have preference for SUMO-2 over SUMO-1 [11, 12].

The consequences of UbL conjugation are numerous. They depend on the UbL type, possibly the nature of UbL chains formed and, obviously, the substrate. As they have been reviewed extensively elsewhere [3, 13–15], only the main physiological roles of Ubiquitylation, SUMOylation and Neddylation are considered hereafter.

The biological outcomes of Ubiquitin conjugation are highly dependent on the chain linkage types, which, due to their diversity and complexity, create the so-called “Ubiquitin code” [14]. The most abundant and best-characterized Ubiquitin chains are long K48-linked ones (>4 Ubiquitins). They constitute a protein degradation signal recognized by the 26S proteasome, which is the main cell proteolytic machinery [16–18]). This discovery led Avram Hershko, Irwin Rose and Aaron Ciechanover to be awarded the Nobel Prize in 2004. It is, however, important to keep in mind that K48-linked Ubiquitin chains can also be involved in signaling events and transcription regulation not involving protein destruction [19–21]. K63-linked chains are best-known as involved in protein-protein interactions, signaling, inflammatory response, DNA repair and ribosomal function [8, 22, 23]. K11 chains were shown to play important roles in cell cycle regulation and the activation of the NF- κ B pathway [24, 25]. Moreover, Ubiquitin can also form linear head-to-tail chains when its C-terminal glycine is linked to the N-terminal methionine of another Ubiquitin [26, 27]. Such chains are formed by the LUBAC complex and play key roles in immune signaling [28]. Finally, Ubiquitin can also be conjugated to protein substrates as monomers, sometimes at multiple sites, to regulate transcription, DNA repair or membrane receptor internalization and possibly degradation [29–31].

More than 6,000 SUMOylated proteins have been identified recently thanks to proteome-wide mass spectrometry approaches [32, 33]. SUMOylation modifies the surface of target proteins and,

thereby, alter their function and fate. In particular, SUMO can recruit SUMO-interacting motifs (SIM)-bearing proteins. However, only a handful of such effectors of SUMOylation have been identified so far. This is, for example, the case of the SUMO-targeted Ubiquitin ligases (StUBLs). These proteins, which include RNF4 [34, 35] and Arkadia/RNF111 [36] harbor multiple SIMs recognizing poly-SUMO-2 chains irrespectively of the substrate they are bound to. As the interaction between SUMO and SIMs is of low affinity, SUMOylation most often stabilizes an already existing interaction rather than promotes a new one. This is typically illustrated by the binding of the DNA helicase Srs2 to SUMO-modified PCNA [37]. Albeit SUMO has been involved in many cellular processes, its best-described functions are nuclear, consistently with a higher accumulation of SUMOylated proteins in the nucleus. In particular, SUMOylation plays key roles in DNA damage repair through the modification of critical proteins involved in this process [38]. SUMO also modifies a high number of proteins involved in gene expression (transcription factors, co-regulators, histones, transcription machinery) and participates in the regulation of transcription [39–43]. SUMOylation often concerns protein complexes comprising multiple SUMOylatable subunits. In this case, the biological outcomes are usually thought to result from SUMOylation of the complex irrespectively of the SUMOylation site or of the SUMOylated proteins within the complexes [44]. SUMOylation is highly regulated by stresses [45]. Some stresses affect limited number of SUMO substrates, while others can alter the activity of the whole pathway by affecting SUMO-conjugating- and/or -deconjugating enzymes. For example, upon proteotoxic stress induced by heat shock, SUMO-2 conjugation is quantitatively rewired to chromatin-bound proteins [46], which prevents protein aggregation and targets them for degradation by the Ubiquitin-proteasome system [47]. Oxidative stress is also a critical regulator of SUMOylation through its ability to induce the reversible inactivation of the SUMO E1 and E2 via the formation of a disulfide bond between their catalytic cysteines [48]. This redox regulation of SUMOylation participates in the activation of ATM kinase and is required for proper DNA damage response [49]. Reactive Oxygen species have also been involved in the regulation of specific SUMO E3 and isopeptidases [50].

Nedd8 (Neural precursor cell-expressed developmentally down-regulated 8) is the closest kin of Ubiquitin, as they share 60% of homology. Cullins, which are key components of the family of the multimeric cullin RING Ubiquitin ligases (CRL) are, by far, the most abundant Neddylated proteins. Cycles of Neddylation/deNeddylation are required for their Ubiquitin ligase activity [51]. Nedd8 is also conjugated to many non-cullin substrates [15]. These include transcription factors, such as p53 [52], TAp73 [53] and E2F1 [54, 55], as well as the VHL (Von-Hippel-

Lindau)[56], BCA3 (Breast-Cancer-Associated protein 3)[57], the chemokine receptor CXCR5 [58] and several ribosomal proteins [59–62]. In these cases, Neddylation is involved in their localization, stabilization or regulation of their interaction with partners [15]. Similarly to SUMOylation, Neddylation has also been implicated in the response to proteotoxic stresses [63].

Oncogenic and tumor suppressor pathways are controlled by UbLs

UbLs, through the variety of proteins they conjugate, are involved in each one of the "Hallmarks of cancer", as defined by Hanahan and Weinberg [64]. For reasons of space, it is impossible to summarize here all cancer-relevant pathways regulated by UbLs. The reader is, therefore, referred to recent comprehensive reviews on this subject [65, 66]. Below, we will focus only on pathways that are controlled by at least two UbLs.

The p53 pathway

The tumor suppressor protein p53 is certainly the best-studied transcription factor in cancer where its major cell protection functions are most often, if not always, lost. Physiologically, p53 participates in multiple cellular functions. They non-exhaustively include regulation of cell cycle and death, senescence, autophagy, DNA damage repair and metabolism. p53 is mutated in approximately 50% of tumors, where its mutations can be associated with oncogenic gains of function. In most of the other tumors, either the p53 gene is deleted or its activity, or that of its protein product, is inhibited following a diversity of mechanisms, which results in inability to control cell proliferation or to induce apoptosis or senescence [67].

The first and best-characterized p53 modification by UbLs is Ubiquitylation [68]. The main cellular E3 ligase for p53 is the MDM2 protein, which maintains low p53 levels under basal conditions via K48-linked chain Ubiquitylation and subsequent proteasomal degradation [69, 70]. Upon genotoxic stress, for example, this Ubiquitylation is arrested, permitting p53 to accumulate and to exert its cell protection functions. On the contrary, upon hyperactivity or amplification of the pro-oncogenic MDM2 gene, p53 is continuously maintained at a low level, favoring tumorigenesis [71]. A similar pro-oncogenic p53 inactivation process occurs in human papilloma virus (HPV) 16/18-infected cervix epithelial cells where the p53-interacting viral protein E6 recruits the cellular E6AP HECT E3 ligase [72, 73]. Interestingly, MDM2 can also mono-Ubiquitylate p53, which entails nuclear export and, thereby, inhibition of transcriptional activity [74]. Such a cytosolic export also impacts other p53 functions, including inhibition of autophagy and induction of apoptosis [75]. Other E3 Ubiquitin ligases such as MSL2 [76] and WWP1 [77]

were shown to target p53 to the cytosol without, however, affecting its proteasomal degradation. Finally, the E3 ligase E4F1 was reported to Ubiquitylate p53 on chromatin. E4F1 increases p53 ability to activate specific transcriptional programs related to cell cycle arrest without affecting its degradation [20](Figure 1)

p53 activity can also be controlled by Neddylation, which involves the E3 ligases activities of MDM2 [52], as well as that of FBOX11 [78]. Neddylation occurs on 3 lysines (370, 372, 373) and reduces p53 transcriptional activity [52, 78–80]. In addition, p53 Neddylation was shown to limit its Ubiquitin-mediated nuclear export [79].

Finally, p53 can also undergo modification by SUMO on its lysine 386 [81–83]. However, the role of this SUMOylation is still debated and might depend on the cellular context [84]. Indeed, p53 SUMOylation was initially described to increase its transcriptional activity [81, 82]. However, other studies showed that SUMOylation is involved in neither p53 localization nor transcriptional activity [85]. SUMOylation was also suggested to regulate p53 subcellular localization. For example, SUMOylation of mouse p53 was shown to be required for nuclear accumulation and enhanced stability in granulosa cells [86]. However, and contrasting with the latter observation, androgen-mediated SUMOylation of p53 was suggested to be important for export of p53 to the cytosol [87] (Figure 1).

The NF- κ B pathway

The NF- κ B pathway is overactive in a vast majority of cancers where it is thought to participate in cancer cell resistance to apoptosis and sustained proliferation. This is especially true in hematological malignancies, where the function of various components of this pathway can be altered, notably by oncogenic mutations or rearrangements/translocations [88].

Under basal physiological conditions, the NF- κ B transcription factor is maintained latent in the cytoplasm through physical interaction with its I κ B α inhibitor [89]. Ubiquitylation is involved in its activation at several steps. A typical example of NF- κ B pathway activation is as follows. In response to an appropriate extracellular stimulus, the RIPK1 (receptor-interacting serine/threonine protein kinase 1) kinase, is modified with non-proteolysis-inducing linear Ubiquitin chains by the LUBAC complex and K11- and K63-linked chains by the cIAP1 (cellular inhibitor of apoptosis protein-1) Ring domain-bearing Ubiquitin E3 factor. These Ubiquitylations serve as a platform for recruiting a downstream kinase effector complex (made up of TAK1, TAB2/3, IKK γ /NEMO), which activates another kinase complex (IKK complex

made up of IKK α and IKK β). Finally, the latter phosphorylates I κ B α , which triggers its subsequent K48-linked Ubiquitylation and is followed by proteasomal degradation. The NF- κ B transcription factor is, thereby, released and can then enter the nucleus to activate its target genes [24].

In the early days of the SUMO field, it was discovered that SUMOylation of I κ B α competes with Ubiquitylation by targeting the same lysine residue (Lys 21)[90]. SUMOylation is also involved in the regulation of NEMO activity. In particular, NEMO gets SUMOylated upon genotoxic stress. This leads to its addressing to the nucleus and subsequent ATM-dependent Ubiquitylation and activation of the IKK complex in the cytoplasm [91].

Finally, it has been suggested that NEMO is Neddylated, which inhibits the NF- κ B pathway [92]. Neddylation was also involved in the regulation of NF- κ B-dependent transcription through modification of BCA3, one of its partners in chromatin. BCA3 Neddylation recruits the deacetylase SIRT1 and, thereby, was proposed to repress transcription of NF- κ B target genes [57].

The TGF β pathway

The TGF- β (Transforming Growth Factor β) pathway generally exerts tumor suppressor activity in normal or premalignant cells but, on the contrary, often promotes tumorigenesis at later stages, including metastasis. Depending on the cell/tumor type, it can be involved in the regulation of cell proliferation, apoptosis, epithelial-mesenchymal transition (EMT) and cell migration [93].

In the canonical pathway, the binding of TGF- β to its cell membrane receptor (made up of two subunits, T β R-I and T β R-II) initiates a cascade of intracellular phosphorylation events. Among the first phosphorylated proteins are Smad-2 and Smad-3, which are transcription factors maintained latent in the cytoplasm in the absence of TGF- β receptor activation. Phosphorylated Smad-2 and -3 then assemble with the Smad-4 protein to form a trimeric complex that translocates into the nucleus where it binds to DNA and stimulates the expression of TGF- β target genes [94]. Interestingly, Ubis control this pathway at multiple and intermingled levels [95]. More specifically, Smad-7 is a cytoplasmic TGF- β -induced negative regulator of the pathway that can recruit Smurf-1 and Smurf-2 (Smad-specific E3 Ubiquitin ligase 1 and -2), two Ubiquitin ligases of the HECT family. These can Ubiquitylate T β R-I, leading to its degradation and, thereby, induce a negative feedback loop on the pathway [96, 97]. T β R-I Ubiquitylation, and consequently its degradation, can, however, be antagonized by the deUbiquitylase Usp15, which

associates with Smurf-2, and act as a positive regulator of the pathway [98]. Interestingly, Smurf-1 and -2 are positively regulated by Neddylation via particular mechanisms. Indeed, Nedd8 is, first, transferred from the Nedd8-conjugating E2 enzyme Ubc12 to the catalytic cysteine of Smurf-1 via the formation of a thioester bond. It is, then, transferred to lysines of Smurf-1. This Neddylation increases the recruitment of Ubiquitin E2(s) and, thereby, activates the Ubiquitylation of Smurf-1 protein substrates [99]. Noteworthy, Smurf-1 and -2 were also shown to bind non-covalently to Nedd8, which also contributes to increasing their Ubiquitin ligase activity [100].

Complexifying the picture, SUMO can also enter into the game at different levels, as diverse components of the TGF- β pathway can undergo SUMOylation with implications in cancer [101]. For example, SUMOylation of T β R-I increases the activation of Smad-3 with, as a biological consequence, enhancement of invasion and metastasis by Ras-transformed cells [102] and suppression of EMT in bladder cancer cells [103]. Smurf-2 is also SUMOylated (on lysines 26 and 369) thanks to the SUMO ligase PIAS3, which increases its Ubiquitin ligase activity and, hence, the degradation of T β R-I. In this case, important outcomes of T β R-I proteolysis consist of decreased TGF- β -induced cell proliferation and reduced invasion by breast cancer cells [104, 105]. Transcription factors downstream of the TGF- β pathway are also SUMOylated with sometimes antagonistic effects. For example, SnoN [106] and Sip1/Zeb2 [107] SUMOylations repress the pathway whereas those of Snail [108] and Slug [109] activate it. Finally, non-covalent SUMO binding might also be involved in the regulation of the TGF- β pathway. As a matter of fact, the already mentioned SUMO-targeted Ubiquitin ligase Arkadia/RNF111 can be recruited via its cluster of SIMs (i.e. most probably due to binding to SUMO-2 chains) to TGF- β pathway-target genes with, as a result, antagonization of the Polycomb repressor complex at the level of their regulatory domains [110].

PML-RARA in Acute Promyelocytic Leukemias

Acute Promyelocytic Leukemias (APL) are a minor subtype (< 10%) of Acute Myeloid Leukemias. In most cases, their main driver tumorigenic mutations consists of a t(15;17) chromosomal translocation engaging the PML and RARA genes, leading to the expression of an oncogenic fusion PML-RAR α . PML, which was initially viewed as a tumor suppressor, was one of the first SUMO substrates to be identified and is one of the most-abundantly SUMOylated proteins in the cell [111–113]. Through self-assembly, it forms the so-called membrane-less PML

nuclear bodies, which recruit many proteins thanks to SUMO-SIM interactions. Recruited proteins can undergo SUMOylation in PML bodies due to the presence of the SUMO E2 Ubc9 within these structures (Sahin *et al*, 2014). Physiologically, PML bodies are seen as structures fine-tuning a variety of cellular activities that include responses to stresses and viral infections, as well as control of cell death, senescence or DNA repair. It has long been known that they are disrupted by the PML-RAR α fusion protein in APL cells [115], which is essential for oncogenesis. Interestingly, the combination of arsenic trioxide and retinoic acid has been shown efficient at curing APL patients. Indeed, it consists of the first successful oncogenic protein-targeted therapy that has been described [116]. In brief, the drug combination entails the polySUMOylation of PML-RAR α , which is followed by the recruitment of the StUbl RNF4 and, hence, its Ubiquitylation and degradation by the proteasome [34, 35]. An important consequence of PML-RAR α destruction is not only induction of cancer cell differentiation into short-lived granulocytes but also abrogation of cancer cell self-renewal through the reformation of PML nuclear bodies and subsequent p53 pathway activation [117].

Deregulations of UbL pathways in cancer

Many UbL enzymes are dysregulated in cancers

Many enzymes and regulators of UbL-conjugating and -deconjugating pathways are dysregulated in various cancers (Table 2) and there is increasing evidence linking these dysregulations to tumorigenesis, cancer progression, metastasis or resistance to anticancer drugs. For reasons of space, it is not possible to describe all dysregulations that have been reported in the literature. Some illustrative examples are, however, summarized below.

Dysregulation of the Ubiquitin pathway enzyme in cancer.

The Ubiquitin pathway is far more complex than the SUMO and Nedd8 pathways, which increases the possibilities of dysregulations associated with cancer (Table 2). Two particularly illustrative examples of dysregulations of this pathway are presented below.

The first one concerns the BIRC1 to -8 (baculovirus IAP repeat-containing protein; IAP standing for inhibitors of apoptosis proteins) family of Ubiquitin E3 ligases. These enzymes play key roles in the activation of the NF- κ B pathway and the inhibition of apoptosis. Their overexpression appeared associated with increased resistance to therapies and adverse prognosis [118]. This is

particular clear for BIRC4 (also called XIAP for X-linked inhibitor of apoptosis protein), which is overexpressed as early as the first stages of breast and colon carcinogenesis. This leads to inhibition of autophagy through the degradation of the autophagy receptor p62 and enhances tumor cell proliferation [119]. BIRC4 is also overexpressed in B-cell lymphomas and associated with weaker response to mitotic spindle poison-based chemotherapies. This is due to its increased stability resulting from its deUbiquitylation by the isopeptidase USP9X that is also overexpressed in the same tumors [120].

The second example deals with E3 ligases from the SCF (Skp1-Cullin1-F-box protein) family, which are also often dysregulated in cancer [121]. This is best-exemplified by various F-box proteins, which are the SCF components responsible for the specificity of substrate recognition [122]. For example, FBXW7 is a well-characterized tumor suppressor thanks to its ability to recruit oncogenic proteins such as c-Myc, c-Jun, c-Myb, Aurora-A for SCF-mediated Ubiquitylation and subsequent proteasomal degradation [123]. Consistently, disabling mutations of FBXW7 are found in numerous cancers. This is, for example, the case in T-cell Acute Lymphocytic Leukemias (T-ALL), with up to 30% of patients presenting mutations in its gene [124] but also in colorectal adenocarcinoma, uterine endometrial carcinoma and bladder carcinoma. Skp2 is another F-Box protein dysregulated in many cancers [125]. Its substrates include the cell cycle inhibitor p27^{Kip1}. Its overexpression in many cancers is associated with a bad prognosis and is generally inversely correlated to p27^{Kip1} expression [126]. The third F-Box, which is often dysregulated in cancer, is β -TRCP (also called FBW1A). It is overexpressed in various cancers, including colorectal tumors where it exerts prooncogenic actions through activating the β -catenin and NF- κ B pathways [127].

Overactivation of the Nedd8 pathway in cancer is often associated with bad prognosis

Strikingly, most enzymes of the Nedd8 pathway are overactivated in lung adenocarcinoma and squamous-cell carcinoma [128]. Along the same line, high Nedd8 expression is an adverse factor in nasopharyngeal carcinoma [99]. Moreover, the Nedd8-activating E1 (formed of the Nae1 and Uba3 subunits) and -conjugating E2 (Ubc12) enzymes were found upregulated in >2/3 of a 322 patient cohort with intra-hepatic cholangiocarcinoma, which was associated with higher global protein Neddylation and tumor progression [129]. Finally, the Jab1/CSN5 protein, which is responsible for deNeddylation of the members of the CRL family of Ubiquitin E3 ligases (see above), was found overexpressed in numerous cancers (breast cancer, ovarian cancer, hepatocellular carcinoma, non-small cell lung cancer, nasopharyngeal carcinoma, etc...) and

associated with adverse prognosis [130].

Dysregulations of the SUMO pathway in cancer

Increasing evidence suggests that both SUMO conjugation- and deconjugation machineries are dysregulated in various cancers (Table 2). Yet, the contributions of these alterations to tumorigenesis have not often been established formally in most cases [65]. Interestingly, the level of Uba2, the catalytic subunit of the SUMO-activating E1 enzyme, is increased in colorectal cancer tissues, the highest Uba2 expression being associated with both the highest colorectal cancer stages and the poorest prognosis [131]. The SUMO-conjugating enzyme Ubc9 is also overexpressed in many cancers. This is the case of hepatocellular carcinomas, where its overexpression participates in the resistance to chemotherapies [132]. HyperSUMOylation has also been described in Myc oncogene-driven lymphomas. This results from a strong transcriptional activation of the expression of most enzymes of the SUMO pathway and is essential for tumorigenesis [133]. Using synthetic lethality screens, it was also shown that Myc-overexpressing breast cancer cells are highly dependent on a functional SUMO pathway for growth and survival [134], pointing to a novel therapeutic windows through targeting SUMOylation enzymes in this cancer type. Finally, deSUMOylases of the SENP family are either up- or down-regulated in cancers. SENP1 is, for example, overexpressed in prostate cancer, where it promotes tumor formation and metastasis [135] and downregulated in osteosarcomas, which is important for the maintenance of cancer stem cells [136].

Targeting UbLs: new perspectives in cancer treatment

Considering their critical roles and their widespread dysregulations in cancer, UbL pathways have emerged as promising therapeutic targets. Considerable efforts have consequently been made worldwide to develop strategies to inhibit their enzyme components [137]. We will focus here on the strategies used to target E1, E2 and E3 factors. For information on the targeting of deconjugating enzymes, the reader is referred to recent review [138, 139]

E1 inhibitors

- Ubiquitin E1 inhibitors

PYR-41 and PYZD-4409 were the first described inhibitors of an Ubiquitin-activating E1 enzyme. They are based on a pyrazolidine cycle and were identified during chemical library screenings [140, 141]. They bind to UBE1 and inhibit the formation of the thioester bond with Ubiquitin. Whether they inactivate UBA6, the second Ubiquitin E1, has however not been

determined yet. PYZD-4409 was shown to induce apoptosis of Acute Myeloid Leukemia cells, with minimal toxicity for normal hematopoietic cells. It also displayed anti-tumoral activity *in vivo* in mice xenografted with human AMLs [140]. A more potent inhibitor of UBE1, TAK-243 (also known as MLN7243), was generated recently by Takeda Pharmaceuticals [142]. It forms an adduct with Ubiquitin and inhibits UBE1 in the nanomolar range. When used on cell lines, it leads to cell cycle arrest, induction of ER stress and impaired DNA damage response. Interestingly, TAK-243 showed (i) anti-tumor activity *in vivo* in immunodeficient mice subcutaneously grafted with various human tumor cell lines [142] and (ii) anti-leukemic activity on primary human AML cells both *in vitro* and *in vivo* after xenografting to immunodeficient mice (PDX) [143]. Finally, in a phase I dose-escalation clinical trial (clinicaltrial.gov identifier: NCT02045095) involving 29 patients with advanced solid tumors, it however, entailed serious adverse events in more than 1/3 of the individuals treated. Its *in vivo* efficacy could be demonstrated by immuno-histochemistry using antibodies directed to either polyUbiquitin chains or Ubiquitylated-histone H2B (uH2B; which is the second most Ubiquitylated proteins in mammalian cells after Ubiquitylated H2A). A second phase I trial is scheduled to start soon with patients undergoing relapse or suffering from hematological malignancies refractory to standard chemotherapies (clinicaltrial.gov identifier: NCT03816319)

- Nedd8 E1 inhibitors

MLN4924, also called TAK-924 or pevonedistat for its clinical form, is the first mechanism-based inhibitor of a UbL E1 enzyme that was designed by the Millenium-Takeda company. As TAK-243, MLN4924 is an ATP-competitive inhibitor of the Nedd8-activating E1 enzyme NAE. It forms a covalent adduct with Nedd8, which is catalyzed by NAE. The adduct cannot be transferred to Nedd8 E2s, blocking the activity of the E1, including *in vivo* [144]. Initial experiments showed that the treatment of immunocompromized mice xenografted with HCT-116 colon cancer cells with MLN4924 led to increased DNA-damage in cancer cells and limited tumor growth [145]. MLN4924 was then shown to have promising antitumoral activity in various preclinical cancer models, including patient-derived xenografts (PDX). Several phase I clinical trials in cancer patients have shown it is well tolerated [146–148] and various phase II trials have now been launched, in particular to treat hematological malignancies. MLN4924 was also shown to synergize, both *in vitro* and *in vivo*, with genotoxic drugs such as Cytarabine [149] or the demethylating agent Azacytidine [150] in AMLs. A phase Ib clinical trial in elderly patients unfit for conventional chemotherapies suggests a potential clinical benefit for the combination of Azacytidine and Pevonedistat [151]. A randomized phase III trial involving 450 patients with

AML, CML (Chronic Myelomonocytic Leukemia) or MDS (Myelodysplastic syndrome) is now ongoing to prove the efficacy of this combination on a large scale (clinicaltrial.gov identifier: NCT03268954)

- SUMO E1 inhibitors

Ginkgolic acid was identified as an inhibitor of the SUMO-activating E1 enzyme during a screening using botanical extracts. This molecule, and its anacardic acid derivative, were shown to bind to the E1 and to inhibit the transfer of SUMO from the E1 to the E2 [152]. Anacardic acid was shown to inhibit cell division, to induce apoptosis and/or to inhibit migration of various cancer cell lines and primary samples [153–157]. It was also shown to limit tumor growth in mice xenografted with human KG1a AML cells [153]. However, anacardic acid is not a potent SUMOylation inhibitors, as it requires concentrations above 25 μ M to inhibit SUMOylation when used on cultured cells [152] and its use in preclinical models is unfortunately limited by its very poor solubility. Moreover, anacardic acid has been shown to inhibit various other enzymes, the best characterized one being the Histone Acetyl Transferase p300 [158]. Recently, Takeda Pharmaceutical has developed ML-792, a mechanism-based inhibitor of the SUMO E1 with nanomolar potency [159]. Similarly to the other UbL E1 inhibitors developed by Takeda Pharmaceutical, it forms a covalent adduct with SUMO that is catalyzed by the SUMO E1. Treatment of cell lines with this inhibitor induces strong mitotic defects, which leads to their apoptosis. Interestingly, ML-792 preferentially affects the proliferation and viability of cancer cells overexpressing the Myc oncogene *in vitro* [159].

E2 inhibitors

Few inhibitors inhibiting UbL-conjugating E2 enzymes have been discovered so far and none of them is used in clinical trials yet.

The NSC697923 molecule was originally identified in a screen for molecules inhibiting the NF- κ B pathway. It actually binds to the catalytic cysteine of the Ubc13-Uev1A Ubiquitin E2 that catalyzes the formation of K63-linked polyUbiquitin chains. Thereby, it prevents the formation of the thioester bond with Ubiquitin [160, 161]. This inhibitor limits the proliferation of diffuse large B-cell lymphoma cells *in vitro* [160]. BAY 11-7082, which was also initially reported as an inhibitor of the NF- κ B pathway, was subsequently shown to inhibit K63-linked polyUbiquitin chains formation by targeting the catalytic cysteines of Ubc13 and UbcH7 [162]. CC0651 is an allosteric inhibitor of the CDC34 Ubiquitin E2, which is associated with Ubiquitylation by cullin-RING ligases. It prevents the discharge of Ubiquitin to acceptor lysines on the target proteins. In

particular, this molecule leads to an accumulation of the CDK inhibitor p27^{kip1}, a target of the SCF complex, which contributes to decreased cancer cell lines proliferation [163, 164]. Using a virtual screening, the triazine analog SMI#9 was identified as an inhibitor of the Ubiquitin E2 Rad6B via binding to its catalytic site [165]. This molecule was shown to enhance cancer cell sensitivity to platinum-based drugs, including *in vivo* [166].

Small molecules targeting the SUMO E2 Ubc9 have also been identified in various screens. Spectomycin B1, which was originally identified as an antibiotic, directly binds to Ubc9 and prevents to formation of the Ubc9-SUMO thioester bond. It inhibits ER α -regulated gene expression and growth of ER α -positive breast-cancer cell lines [167, 168]. The flavonoid derivative 2-D08 was found to inhibit the transfer of SUMO from Ubc9 to target proteins [169]. Moreover, 2-D08 also sensitized non-promyelocytic AML cells to retinoids-induced differentiation and death both *in vitro* and *in vivo* [170]. Unfortunately, all of these SUMO E2 inhibitors have low potency and poor solubility, which prevents their use in therapy.

E3 inhibitors

Inhibiting E1 or E2 enzymes affects the activity of the whole UbL pathway, which may entail deleterious effects on normal, non-cancerous cells. Targeting E3s is consequently considered as a more specific and, potentially, less toxic approach in living individuals. To date, no molecule targeting SUMO or Nedd8 E3s has been identified. By contrast, many molecules targeting Ubiquitin E3s have been discovered [171], as illustrated below in the case of MDM2 and IAPs.

- MDM2 inhibitors

As mentioned previously, MDM2 is physiologically responsible for the Ubiquitylation of the tumor suppressor p53, but is overexpressed in numerous cancers, preventing p53 pathway activation, in particular in case of genotoxic insults. Inhibiting MDM2 pharmacologically therefore constitutes an intense research area with several molecules in preclinical development and others already in clinical trials [172]. Nutlins are imidazoline compounds, which compete with p53 for the binding to MDM2. Such a competition restores the p53 pathway via inhibiting p53 degradation and induces cell cycle arrest and apoptosis of cancer cell lines both *in vitro* and *in vivo* [173]. RG7112, a member of the Nutlin family, was the first MDM2 inhibitor to be used in phase I clinical trials, in particular for liposarcoma- [174] and hematological malignancies-presenting patients [175]. This compound was shown to efficiently activate p53 in these tumors and a fraction of patients showed a clinical response. However, therapy-related adverse events

were observed in most of treated individuals. Quite similarly to Nutlins, MI-219 mimicks p53 primary structure motifs, binds to MDM2 and prevents its association with p53. It permits robust inhibition of tumor growth *in vivo* without affecting normal tissues in mouse cancer models [176]. AMG-232 is also to be added to the list of small molecules inhibiting the p53-MDM2 interaction [177]. This molecule, which can be administered orally and is highly potent, is currently tested in phase I and II clinical trials [178]. Another emerging approach to target the p53/MDM2 interaction is the use of stapled peptides. These peptides mimic α -helices through side-chain crosslinking between non-natural amino acids introduced in the peptide during synthesis [179]. ALRN-6924 is a stapled peptide that efficiently disrupts the p53/MDM2 interaction, activates p53-dependent transcriptional programs and shows a robust antileukemic activity in mouse preclinical models [180]. Phase I/II trials are ongoing in patients with solid tumors and hematological malignancies (clinicaltrial.gov identifier: NCT02264613, NCT02909972).

- IAP inhibitors

As presented above, IAP/BIRC family members are Ubiquitin E3 ligases, which inhibit apoptosis by preventing, directly or indirectly, the activation of Caspase-3 and -9. SMAC is a mitochondrial antagonist of IAPs binding to their BIR domain and, thereby, preventing their activation. SMAC-mimetics mimicking the N-terminal residues of SMAC induce the dimerization of IAPs, which is followed by auto-Ubiquitylation and subsequent degradation [181]. These molecules were shown to have anti-tumoral activity as single agents or when combined with cytotoxic agents in various preclinical models. For example, Birinapan is a bivalent SMAC mimetic that was shown to activate RIPK-1-dependent apoptosis in relapsed and refractory Acute Lymphoblastic Leukemias (ALL) and to efficiently limit tumor growth *in vivo* [182]. It was also shown to synergize with various drugs, including the DNA-demethylating agent 5-azacytidine in AMLs [183]. A phase I clinical trial showed that it is well tolerated and leads to an important reduction of cIAP1 and the activation of cell-death pathways in the tumors and PBMCs (peripheral blood mononuclear cells) from the treated patients [184]. Similar results were obtained with LCL161, another SMAC mimetic under clinical development [185].

Conclusion

In conclusion, SUMO, Nedd8 and Ubiquitin play key roles in the control of essential cellular pathways and functions that are often dysregulated in cancer and/or participate to cancer response to therapies. Moreover, enzymes of SUMO, Nedd8 and Ubiquitin pathways are also dysregulated

in many tumor types. They therefore constitute attractive therapeutic targets. Intense efforts by academic and industry laboratories have recently been made to discover small pharmacological agents targeting them. A number of these are now being tested in early phase clinical trials and others are about to enter clinical testing. This might pave the way to better cancer treatment.

Acknowledgements

We are grateful to all members of the "Oncogenesis and Immunotherapy" group of IGMM for support and fruitful discussions. Funding was provided by the CNRS, Ligue Nationale contre le Cancer (Programme Equipe Labellisée), INCA (ROSAML), Association Laurette Fugain (contract ALF-2017/02), the Fondation ARC (to PG), the Fédération Leucémie Espoir, The EpiGenMed Labex and the ANR under the "Investissements d'avenir" programme (ANR-16-IDEX-0006).

References

1. van der Veen AG, Ploegh HL (2012) Ubiquitin-Like Proteins. *Annu Rev Biochem* 81:323–357. <https://doi.org/10.1146/annurev-biochem-093010-153308>
2. Vijay-Kumar S, Bugg CE, Cook WJ (1987) Structure of ubiquitin refined at 1.8 Å resolution. *J Mol Biol* 194:531–544
3. Kerscher O, Felberbaum R, Hochstrasser M (2006) Modification of Proteins by Ubiquitin and Ubiquitin-Like Proteins. *Annu Rev Cell Dev Biol* 22:159–180. <https://doi.org/10.1146/annurev.cellbio.22.010605.093503>
4. Cappadocia L, Lima CD (2018) Ubiquitin-like Protein Conjugation: Structures, Chemistry, and Mechanism. *Chem Rev* 118:889–918. <https://doi.org/10.1021/acs.chemrev.6b00737>
5. Zheng N, Shabek N (2017) Ubiquitin Ligases: Structure, Function, and Regulation. *Annu Rev Biochem* 86:129–157. <https://doi.org/10.1146/annurev-biochem-060815-014922>
6. Pichler A, Fatouros C, Lee H, Eisenhardt N (2017) SUMO conjugation - a mechanistic view. *Biomol Concepts* 8:13–36. <https://doi.org/10.1515/bmc-2016-0030>
7. Komander D, Rape M (2012) The Ubiquitin Code. *Annu Rev Biochem* 81:203–229. <https://doi.org/10.1146/annurev-biochem-060310-170328>
8. Yau R, Rape M (2016) The increasing complexity of the ubiquitin code. *Nat Cell Biol* 18:579–586. <https://doi.org/10.1038/ncb3358>
9. Clague MJ, Urbé S, Komander D (2019) Breaking the chains: deubiquitylating enzyme specificity begets function. *Nat Rev Mol Cell Biol*. <https://doi.org/10.1038/s41580-019-0099-1>

10. Kunz K, Piller T, Müller S (2018) SUMO-specific proteases and isopeptidases of the SENP family at a glance. *J Cell Sci* 131:jcs211904. <https://doi.org/10.1242/jcs.211904>
11. Gong L, Yeh ETH (2006) Characterization of a Family of Nucleolar SUMO-specific Proteases with Preference for SUMO-2 or SUMO-3. *J Biol Chem* 281:15869–15877. <https://doi.org/10.1074/jbc.M511658200>
12. Schulz S, Chachami G, Kozaczekiewicz L, et al (2012) Ubiquitin-specific protease-like 1 (USPL1) is a SUMO isopeptidase with essential, non-catalytic functions. *EMBO Rep* 13:930–938. <https://doi.org/10.1038/embor.2012.125>
13. Flotho A, Melchior F (2013) Sumoylation: A Regulatory Protein Modification in Health and Disease. *Annu Rev Biochem* 82:357–385. <https://doi.org/10.1146/annurev-biochem-061909-093311>
14. Kwon YT, Ciechanover A (2017) The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy. *Trends Biochem Sci* 42:873–886. <https://doi.org/10.1016/j.tibs.2017.09.002>
15. Enchev RI, Schulman BA, Peter M (2015) Protein neddylation: beyond cullin–RING ligases. *Nat Rev Mol Cell Biol* 16:30–44. <https://doi.org/10.1038/nrm3919>
16. Chau V, Tobias JW, Bachmair A, et al (1989) A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. *Science* 243:1576–1583
17. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. *Physiol Rev* 82:373–428. <https://doi.org/10.1152/physrev.00027.2001>
18. Ciechanover A (2017) Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. *Best Pract Res Clin Haematol* 30:341–355. <https://doi.org/10.1016/j.beha.2017.09.001>
19. Flick K, Raasi S, Zhang H, et al (2006) A ubiquitin-interacting motif protects polyubiquitinated Met4 from degradation by the 26S proteasome. *Nat Cell Biol* 8:509–515. <https://doi.org/10.1038/ncb1402>
20. Le Cam L, Linares LK, Paul C, et al (2006) E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. *Cell* 127:775–788. <https://doi.org/10.1016/j.cell.2006.09.031>
21. Yao T, Ndoja A (2012) Regulation of gene expression by the ubiquitin-proteasome system. *Semin Cell Dev Biol* 23:523–529. <https://doi.org/10.1016/j.semcdb.2012.02.006>
22. Lee BL, Singh A, Mark Glover JN, et al (2017) Molecular Basis for K63-Linked Ubiquitination Processes in Double-Strand DNA Break Repair: A Focus on Kinetics and Dynamics. *J Mol Biol* 429:3409–3429. <https://doi.org/10.1016/j.jmb.2017.05.029>

23. Wu X, Karin M (2015) Emerging roles of Lys63-linked polyubiquitylation in immune responses. *Immunol Rev* 266:161–174. <https://doi.org/10.1111/imr.12310>
24. Schmukle AC, Walczak H (2012) No one can whistle a symphony alone – how different ubiquitin linkages cooperate to orchestrate NF- κ B activity. *J Cell Sci* 125:549–559. <https://doi.org/10.1242/jcs.091793>
25. Wickliffe KE, Williamson A, Meyer H-J, et al (2011) K11-linked ubiquitin chains as novel regulators of cell division. *Trends Cell Biol* 21:656–663. <https://doi.org/10.1016/j.tcb.2011.08.008>
26. Kirisako T, Kamei K, Murata S, et al (2006) A ubiquitin ligase complex assembles linear polyubiquitin chains. *EMBO J* 25:4877–4887. <https://doi.org/10.1038/sj.emboj.7601360>
27. Rittinger K, Ikeda F (2017) Linear ubiquitin chains: enzymes, mechanisms and biology. *Open Biol* 7:. <https://doi.org/10.1098/rsob.170026>
28. Spit M, Rieser E, Walczak H (2019) Linear ubiquitination at a glance. *J Cell Sci* 132:jcs208512. <https://doi.org/10.1242/jcs.208512>
29. Haglund K, Sigismund S, Polo S, et al (2003) Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. *Nat Cell Biol* 5:461–466. <https://doi.org/10.1038/ncb983>
30. Haglund K, Di Fiore PP, Dikic I (2003) Distinct monoubiquitin signals in receptor endocytosis. *Trends Biochem Sci* 28:598–604. <https://doi.org/10.1016/j.tibs.2003.09.005>
31. Sadowski M, Suryadinata R, Tan AR, et al (2012) Protein monoubiquitination and polyubiquitination generate structural diversity to control distinct biological processes. *IUBMB Life* 64:136–142. <https://doi.org/10.1002/iub.589>
32. Hendriks IA, Vertegaal ACO (2016) A comprehensive compilation of SUMO proteomics. *Nat Rev Mol Cell Biol* 17:581–595. <https://doi.org/10.1038/nrm.2016.81>
33. Hendriks IA, Lyon D, Young C, et al (2017) Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. *Nat Struct Mol Biol* 24:325–336. <https://doi.org/10.1038/nsmb.3366>
34. Tatham MH, Geoffroy M-C, Shen L, et al (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. *Nat Cell Biol* 10:538–546. <https://doi.org/10.1038/ncb1716>
35. Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al (2008) Arsenic degrades PML or PML–RAR α through a SUMO-triggered RNF4/ubiquitin-mediated pathway. *Nat Cell Biol* 10:547–555. <https://doi.org/10.1038/ncb1717>
36. Sun H, Hunter T (2012) PolySUMO-binding proteins identified through a string search. *J Biol Chem*. <https://doi.org/10.1074/jbc.M112.410985>

37. Armstrong AA, Mohideen F, Lima CD (2012) Recognition of SUMO-modified PCNA requires tandem receptor motifs in Srs2. *Nature* 483:59–63. <https://doi.org/10.1038/nature10883>
38. Garvin AJ, Morris JR (2017) SUMO, a small, but powerful, regulator of double-strand break repair. *Philos Trans R Soc B Biol Sci* 372:. <https://doi.org/10.1098/rstb.2016.0281>
39. Neyret-Kahn H, Benhamed M, Ye T, et al (2013) Sumoylation at chromatin governs coordinated repression of a transcriptional program essential for cell growth and proliferation. *Genome Res* 23:1563–79. <https://doi.org/10.1101/gr.154872.113>
40. Cossec J-C, Theurillat I, Chica C, et al (2018) SUMO Safeguards Somatic and Pluripotent Cell Identities by Enforcing Distinct Chromatin States. *Cell Stem Cell* 23:742-757.e8. <https://doi.org/10.1016/j.stem.2018.10.001>
41. Rosonina E, Akhter A, Dou Y, et al (2017) Regulation of transcription factors by sumoylation. *Transcription* 8:220–231. <https://doi.org/10.1080/21541264.2017.1311829>
42. Tempé D, Vives E, Brockly F, et al (2014) SUMOylation of the inducible (c-Fos:c-Jun)/AP-1 transcription complex occurs on target promoters to limit transcriptional activation. *Oncogene* 33:921–927. <https://doi.org/10.1038/onc.2013.4>
43. Chymkowitch P, P AN, Aanes H, et al (2015) Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes. *Genome Res* 25:897–906. <https://doi.org/10.1101/gr.185793.114>
44. Psakhye I, Jentsch S (2012) Protein Group Modification and Synergy in the SUMO Pathway as Exemplified in DNA Repair. *Cell* 151:807–20. <https://doi.org/10.1016/j.cell.2012.10.021>
45. Tempé D, Piechaczyk M, Bossis G (2008) SUMO under stress. *Biochem Soc Trans* 36:874–878. <https://doi.org/10.1042/BST0360874>
46. Seifert A, Schofield P, Barton GJ, Hay RT (2015) Proteotoxic stress reprograms the chromatin landscape of SUMO modification. *Sci Signal* 8:rs7–rs7. <https://doi.org/10.1126/scisignal.aaa2213>
47. Liebelt F, Sebastian RM, Moore CL, et al (2019) SUMOylation and the HSF1-Regulated Chaperone Network Converge to Promote Proteostasis in Response to Heat Shock. *Cell Rep* 26:236-249.e4. <https://doi.org/10.1016/j.celrep.2018.12.027>
48. Bossis G, Melchior F (2006) Regulation of SUMOylation by Reversible Oxidation of SUMO Conjugating Enzymes. *Mol Cell* 21:349–357. <https://doi.org/10.1016/j.molcel.2005.12.019>
49. Stankovic- Valentin N, Drzewicka K, König C, et al (2016) Redox regulation of SUMO enzymes is required for ATM activity and survival in oxidative stress. *EMBO J* 35:1312–1329. <https://doi.org/10.15252/emboj.201593404>

50. Stankovic-Valentin N, Melchior F (2018) Control of SUMO and Ubiquitin by ROS: Signaling and disease implications. *Mol Aspects Med* 63:3–17. <https://doi.org/10.1016/j.mam.2018.07.002>
51. Deshaies RJ, Emberley ED, Saha A (2010) Control of cullin-ring ubiquitin ligase activity by nedd8. *Subcell Biochem* 54:41–56. https://doi.org/10.1007/978-1-4419-6676-6_4
52. Xirodimas DP, Saville MK, Bourdon J-C, et al (2004) Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. *Cell* 118:83–97. <https://doi.org/10.1016/j.cell.2004.06.016>
53. Watson IR, Blanch A, Lin DCC, et al (2006) Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. *J Biol Chem* 281:34096–34103. <https://doi.org/10.1074/jbc.M603654200>
54. Loftus SJ, Liu G, Carr SM, et al (2012) NEDDylation regulates E2F-1-dependent transcription. *EMBO Rep* 13:811–818. <https://doi.org/10.1038/embor.2012.113>
55. Aoki I, Higuchi M, Gotoh Y (2013) NEDDylation controls the target specificity of E2F1 and apoptosis induction. *Oncogene* 32:3954–3964. <https://doi.org/10.1038/onc.2012.428>
56. Russell RC, Ohh M (2008) NEDD8 acts as a “molecular switch” defining the functional selectivity of VHL. *EMBO Rep* 9:486–491. <https://doi.org/10.1038/embor.2008.19>
57. Gao F, Cheng J, Shi T, Yeh ETH (2006) Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFκB-dependent transcription. *Nat Cell Biol* 8:1171–1177. <https://doi.org/10.1038/ncb1483>
58. Renaudin X, Guervilly J-H, Aoufouchi S, Rosselli F (2014) Proteomic analysis reveals a FANCA-modulated neddylation pathway involved in CXCR5 membrane targeting and cell mobility. *J Cell Sci* 127:3546–3554. <https://doi.org/10.1242/jcs.150706>
59. Sundqvist A, Liu G, Mirsalotis A, Xirodimas DP (2009) Regulation of nucleolar signalling to p53 through NEDDylation of L11. *EMBO Rep* 10:1132–1139. <https://doi.org/10.1038/embor.2009.178>
60. Mahata B, Sundqvist A, Xirodimas DP (2012) Recruitment of RPL11 at promoter sites of p53-regulated genes upon nucleolar stress through NEDD8 and in an Mdm2-dependent manner. *Oncogene* 31:3060–3071. <https://doi.org/10.1038/onc.2011.482>
61. Zhang J, Bai D, Ma X, et al (2014) hCINAP is a novel regulator of ribosomal protein-HDM2-p53 pathway by controlling NEDDylation of ribosomal protein S14. *Oncogene* 33:246–254. <https://doi.org/10.1038/onc.2012.560>
62. El Motiam A, Vidal S, de la Cruz-Herrera CF, et al (2019) Interplay between SUMOylation and NEDDylation regulates RPL11 localization and function. *FASEB J Off Publ Fed Am Soc Exp Biol* 33:643–651. <https://doi.org/10.1096/fj.201800341RR>

63. Maghames CM, Lobato-Gil S, Perrin A, et al (2018) NEDDylation promotes nuclear protein aggregation and protects the Ubiquitin Proteasome System upon proteotoxic stress. *Nat Commun* 9:4376. <https://doi.org/10.1038/s41467-018-06365-0>
64. Hanahan D, Weinberg RA (2011) Hallmarks of Cancer: The Next Generation. *Cell* 144:646–674. <https://doi.org/10.1016/j.cell.2011.02.013>
65. Seeler J-S, Dejean A (2017) SUMO and the robustness of cancer. *Nat Rev Cancer* 17:184–197. <https://doi.org/10.1038/nrc.2016.143>
66. Zhou L, Zhang W, Sun Y, Jia L (2018) Protein neddylation and its alterations in human cancers for targeted therapy. *Cell Signal* 44:92–102. <https://doi.org/10.1016/j.cellsig.2018.01.009>
67. Niazi S, Purohit M, Niazi JH (2018) Role of p53 circuitry in tumorigenesis: A brief review. *Eur J Med Chem* 158:7–24. <https://doi.org/10.1016/j.ejmech.2018.08.099>
68. Sane S, Rezvani K (2017) Essential Roles of E3 Ubiquitin Ligases in p53 Regulation. *Int J Mol Sci* 18:. <https://doi.org/10.3390/ijms18020442>
69. Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS Lett* 420:25–27. [https://doi.org/10.1016/S0014-5793\(97\)01480-4](https://doi.org/10.1016/S0014-5793(97)01480-4)
70. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. *Nature* 387:299–303. <https://doi.org/10.1038/387299a0>
71. Carr MI, Jones SN (2016) Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis. *Transl Cancer Res* 5:707–724. <https://doi.org/10.21037/tcr.2016.11.75>
72. Scheffner M, Werness BA, Huibregtse JM, et al (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. *Cell* 63:1129–1136
73. Martinez-Zapien D, Ruiz FX, Poirson J, et al (2016) Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. *Nature* 529:541–545. <https://doi.org/10.1038/nature16481>
74. Li M, Brooks CL, Wu-Baer F, et al (2003) Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2. *Science* 302:1972–1975. <https://doi.org/10.1126/science.1091362>
75. Lee JT, Gu W (2010) The multiple levels of regulation by p53 ubiquitination. *Cell Death Differ* 17:86–92. <https://doi.org/10.1038/cdd.2009.77>
76. Kruse J-P, Gu W (2009) MSL2 Promotes Mdm2-independent Cytoplasmic Localization of p53. *J Biol Chem* 284:3250–3263. <https://doi.org/10.1074/jbc.M805658200>

77. Laine A, Ronai Z (2007) Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. *Oncogene* 26:1477–1483. <https://doi.org/10.1038/sj.onc.1209924>
78. Abida WM, Nikolaev A, Zhao W, et al (2007) FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. *J Biol Chem* 282:1797–1804. <https://doi.org/10.1074/jbc.M609001200>
79. Liu G, Xirodimas DP (2010) NUB1 promotes cytoplasmic localization of p53 through cooperation of the NEDD8 and ubiquitin pathways. *Oncogene* 29:2252–2261. <https://doi.org/10.1038/onc.2009.494>
80. Batuello CN, Hauck PM, Gendron JM, et al (2015) Src phosphorylation converts Mdm2 from a ubiquitinating to a neddylation E3 ligase. *Proc Natl Acad Sci U S A* 112:1749–1754. <https://doi.org/10.1073/pnas.1416656112>
81. Rodriguez MS, Desterro JMP, Lain S, et al (1999) SUMO-1 modification activates the transcriptional response of p53. *EMBO J* 18:6455–6461. <https://doi.org/10.1093/emboj/18.22.6455>
82. Gostissa M, Hengstermann A, Fogal V, et al (1999) Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. *EMBO J* 18:6462–6471. <https://doi.org/10.1093/emboj/18.22.6462>
83. Muller S, Berger M, Lehembre F, et al (2000) c-Jun and p53 activity is modulated by SUMO-1 modification. *J Biol Chem* 275:13321–13329
84. Stehmeier P, Muller S (2009) Regulation of p53 family members by the ubiquitin-like SUMO system. *DNA Repair* 8:491–498. <https://doi.org/10.1016/j.dnarep.2009.01.002>
85. Kwek SS, Derry J, Tyner AL, et al (2001) Functional analysis and intracellular localization of p53 modified by SUMO-1. *Oncogene* 20:2587–2599. <https://doi.org/10.1038/sj.onc.1204362>
86. Liu X-M, Yang F-F, Yuan Y-F, et al (2013) SUMOylation of Mouse p53b by SUMO-1 Promotes Its Pro-Apoptotic Function in Ovarian Granulosa Cells. *PLOS ONE* 8:e63680. <https://doi.org/10.1371/journal.pone.0063680>
87. Ashikari D, Takayama K, Tanaka T, et al (2017) Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer. *Oncogene* 36:6272–6281. <https://doi.org/10.1038/onc.2017.225>
88. Imbert V, Peyron J-F (2017) NF- κ B in Hematological Malignancies. *Biomedicines* 5:. <https://doi.org/10.3390/biomedicines5020027>
89. Seo J, Kim MW, Bae K-H, et al (2019) The roles of ubiquitination in extrinsic cell death pathways and its implications for therapeutics. *Biochem Pharmacol* 162:21–40. <https://doi.org/10.1016/j.bcp.2018.11.012>

90. Desterro JMP, Rodriguez MS, Hay RT (1998) SUMO-1 Modification of I κ B α Inhibits NF- κ B Activation. *Mol Cell* 2:233–239. [https://doi.org/10.1016/S1097-2765\(00\)80133-1](https://doi.org/10.1016/S1097-2765(00)80133-1)
91. Huang TT, Wuerzberger-Davis SM, Wu Z-H, Miyamoto S (2003) Sequential modification of NEMO/IKK γ by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. *Cell* 115:565–576
92. Noguchi K, Okumura F, Takahashi N, et al (2011) TRIM40 promotes neddylation of IKK γ and is downregulated in gastrointestinal cancers. *Carcinogenesis* 32:995–1004. <https://doi.org/10.1093/carcin/bgr068>
93. Colak S, ten Dijke P (2017) Targeting TGF- β Signaling in Cancer. *Trends Cancer* 3:56–71. <https://doi.org/10.1016/j.trecan.2016.11.008>
94. Budi EH, Duan D, Derynck R (2017) Transforming Growth Factor- β Receptors and Smads: Regulatory Complexity and Functional Versatility. *Trends Cell Biol* 27:658–672. <https://doi.org/10.1016/j.tcb.2017.04.005>
95. Iyengar PV (2017) Regulation of Ubiquitin Enzymes in the TGF- β Pathway. *Int J Mol Sci* 18:877. <https://doi.org/10.3390/ijms18040877>
96. Kavsak P, Rasmussen RK, Causing CG, et al (2000) Smad7 Binds to Smurf2 to Form an E3 Ubiquitin Ligase that Targets the TGF β Receptor for Degradation. *Mol Cell* 6:1365–1375. [https://doi.org/10.1016/S1097-2765\(00\)00134-9](https://doi.org/10.1016/S1097-2765(00)00134-9)
97. Ebisawa T, Fukuchi M, Murakami G, et al (2001) Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. *J Biol Chem* 276:12477–12480. <https://doi.org/10.1074/jbc.C100008200>
98. Eichhorn PJA, Rodón L, González-Juncà A, et al (2012) USP15 stabilizes TGF- β receptor I and promotes oncogenesis through the activation of TGF- β signaling in glioblastoma. *Nat Med* 18:429–435. <https://doi.org/10.1038/nm.2619>
99. Xie P, Zhang M, He S, et al (2014) The covalent modifier Nedd8 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis. *Nat Commun* 5:3733. <https://doi.org/10.1038/ncomms4733>
100. He S, Cao Y, Xie P, et al (2017) The Nedd8 Non-covalent Binding Region in the Smurf HECT Domain is Critical to its Ubiquitin Ligase Function. *Sci Rep* 7:. <https://doi.org/10.1038/srep41364>
101. Chanda A, Sarkar A, Bonni S (2018) The SUMO System and TGF β Signaling Interplay in Regulation of Epithelial-Mesenchymal Transition: Implications for Cancer Progression. *Cancers* 10:. <https://doi.org/10.3390/cancers10080264>
102. Kang JS, Saunier EF, Akhurst RJ, Derynck R (2008) The type I TGF- β receptor is covalently modified and regulated by sumoylation. *Nat Cell Biol* 10:654–664. <https://doi.org/10.1038/ncb1728>

103. Tan M, Zhang D, Zhang E, et al (2017) SENP2 suppresses epithelial-mesenchymal transition of bladder cancer cells through deSUMOylation of TGF- β RI. *Mol Carcinog* 56:2332–2341. <https://doi.org/10.1002/mc.22687>
104. Chandhoke AS, Karve K, Dadakhujaev S, et al (2016) The ubiquitin ligase Smurf2 suppresses TGF β -induced epithelial–mesenchymal transition in a sumoylation-regulated manner. *Cell Death Differ* 23:876–888. <https://doi.org/10.1038/cdd.2015.152>
105. Chandhoke AS, Chanda A, Karve K, et al (2017) The PIAS3-Smurf2 sumoylation pathway suppresses breast cancer organoid invasiveness. *Oncotarget* 8:21001–21014. <https://doi.org/10.18632/oncotarget.15471>
106. Ikeuchi Y, Dadakhujaev S, Chandhoke AS, et al (2014) TIF1 γ Protein Regulates Epithelial-Mesenchymal Transition by Operating as a Small Ubiquitin-like Modifier (SUMO) E3 Ligase for the Transcriptional Regulator SnoN1. *J Biol Chem* 289:25067–25078. <https://doi.org/10.1074/jbc.M114.575878>
107. Long J, Zuo D, Park M (2005) Pc2-mediated Sumoylation of Smad-interacting Protein 1 Attenuates Transcriptional Repression of E-cadherin. *J Biol Chem* 280:35477–35489. <https://doi.org/10.1074/jbc.M504477200>
108. Gudey SK, Sundar R, Heldin C-H, et al (2017) Pro-invasive properties of Snail1 are regulated by sumoylation in response to TGF β stimulation in cancer. *Oncotarget* 8:97703–97726. <https://doi.org/10.18632/oncotarget.20097>
109. Xie Y, Liu S, Lu W, et al (2014) Slug regulates E- cadherin repression via p19Arf in prostate tumorigenesis. *Mol Oncol* 8:1355–1364. <https://doi.org/10.1016/j.molonc.2014.05.006>
110. Sun H, Liu Y, Hunter T (2014) Multiple Arkadia/RNF111 Structures Coordinate Its Polycomb Body Association and Transcriptional Control. *Mol Cell Biol* 34:2981–2995. <https://doi.org/10.1128/MCB.00036-14>
111. Müller S, Matunis MJ, Dejean A (1998) Conjugation with the ubiquitin- related modifier SUMO- 1 regulates the partitioning of PML within the nucleus. *EMBO J* 17:61–70. <https://doi.org/10.1093/emboj/17.1.61>
112. Kamitani T, Nguyen HP, Kito K, et al (1998) Covalent Modification of PML by the Sentrin Family of Ubiquitin-like Proteins. *J Biol Chem* 273:3117–3120. <https://doi.org/10.1074/jbc.273.6.3117>
113. Duprez E, Saurin AJ, Desterro JM, et al (1999) SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. *J Cell Sci* 112:381–393
114. Sahin U, Ferhi O, Jeanne M, et al (2014) Oxidative stress–induced assembly of PML nuclear bodies controls sumoylation of partner proteins. *J Cell Biol* 204:931–945. <https://doi.org/10.1083/jcb.201305148>

115. Weis K, Rambaud S, Lavau C, et al (1994) Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. *Cell* 76:345–356
116. de Thé H (2018) Differentiation therapy revisited. *Nat Rev Cancer* 18:117–127. <https://doi.org/10.1038/nrc.2017.103>
117. Ablain J, Rice K, Soilihi H, et al (2014) Activation of a promyelocytic leukemia–tumor protein 53 axis underlies acute promyelocytic leukemia cure. *Nat Med* 20:167–174. <https://doi.org/10.1038/nm.3441>
118. Mohamed MS, Bishr MK, Almutairi FM, Ali AG (2017) Inhibitors of apoptosis: clinical implications in cancer. *Apoptosis* 22:1487–1509. <https://doi.org/10.1007/s10495-017-1429-4>
119. Huang X, Wang X, Yuan X, et al (2019) XIAP facilitates breast and colon carcinoma growth via promotion of p62 depletion through ubiquitination-dependent proteasomal degradation. *Oncogene* 38:1448. <https://doi.org/10.1038/s41388-018-0513-8>
120. Engel K, Rudelius M, Slawska J, et al (2016) USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B- cell lymphoma. *EMBO Mol Med* 8:851–862. <https://doi.org/10.15252/emmm.201506047>
121. Zheng N, Zhou Q, Wang Z, Wei W (2016) Recent advances in SCF ubiquitin ligase complex: clinical implications. *Biochim Biophys Acta* 1866:12–22. <https://doi.org/10.1016/j.bbcan.2016.05.001>
122. Uddin S, Bhat AA, Krishnankutty R, et al (2016) Involvement of F-BOX proteins in progression and development of human malignancies. *Semin Cancer Biol* 36:18–32. <https://doi.org/10.1016/j.semcancer.2015.09.008>
123. Shimizu K, Nihira NT, Inuzuka H, Wei W (2018) Physiological functions of FBW7 in cancer and metabolism. *Cell Signal* 46:15–22. <https://doi.org/10.1016/j.cellsig.2018.02.009>
124. Asnafi V, Buzyn A, Noir SL, et al (2009) NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. *Blood* 113:3918–3924. <https://doi.org/10.1182/blood-2008-10-184069>
125. Hao Z, Huang S (2015) E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy. *Front Biosci Landmark Ed* 20:474–490
126. Masuda T, Inoue H, Sonoda H, et al (2002) Clinical and Biological Significance of S-Phase Kinase-associated Protein 2 (Skp2) Gene Expression in Gastric Carcinoma: Modulation of Malignant Phenotype by Skp2 Overexpression, Possibly via p27 Proteolysis. *Cancer Res* 62:3819–3825

127. Ougolkov A, Zhang B, Yamashita K, et al (2004) Associations Among β -TrCP, an E3 Ubiquitin Ligase Receptor, β -Catenin, and NF- κ B in Colorectal Cancer. *JNCI J Natl Cancer Inst* 96:1161–1170. <https://doi.org/10.1093/jnci/djh219>
128. Li L, Wang M, Yu G, et al (2014) Overactivated Neddylolation Pathway as a Therapeutic Target in Lung Cancer. *JNCI J Natl Cancer Inst* 106:. <https://doi.org/10.1093/jnci/dju083>
129. Gao Q, Yu G-Y, Shi J-Y, et al (2014) Neddylolation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target. *Oncotarget* 5:7820–7832. <https://doi.org/10.18632/oncotarget.2309>
130. Guo Z, Wang Y, Zhao Y, et al (2019) The pivotal oncogenic role of Jab1/CSN5 and its therapeutic implications in human cancer. *Gene* 687:219–227. <https://doi.org/10.1016/j.gene.2018.11.061>
131. He P, Sun X, Cheng H-J, et al (2018) UBA2 promotes proliferation of colorectal cancer. *Mol Med Rep* 18:5552–5562. <https://doi.org/10.3892/mmr.2018.9613>
132. Fang S, Qiu J, Wu Z, et al (2017) Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin. *Oncotarget* 8:49783–49795. <https://doi.org/10.18632/oncotarget.17939>
133. Hoellein A, Fallahi M, Schoeffmann S, et al (2014) Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. *Blood* 124:2081–2090. <https://doi.org/10.1182/blood-2014-06-584524>
134. Kessler JD, Kahle KT, Sun T, et al (2011) A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis. *Science* 335:348–53. <https://doi.org/10.1126/science.1212728>
135. Wang Q, Xia N, Li T, et al (2013) SUMO-specific protease 1 promotes prostate cancer progression and metastasis. *Oncogene* 32:2493–2498. <https://doi.org/10.1038/onc.2012.250>
136. Liu F, Li L, Li Y, et al (2018) Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV. *Int J Oncol* 53:2010–2020. <https://doi.org/10.3892/ijo.2018.4537>
137. Huang X, Dixit VM (2016) Drugging the undruggables: exploring the ubiquitin system for drug development. *Cell Res* 26:484–498. <https://doi.org/10.1038/cr.2016.31>
138. Farshi P, Deshmukh RR, Nwankwo JO, et al (2015) Deubiquitinases (DUBs) and DUB inhibitors: a patent review. *Expert Opin Ther Pat* 25:1191–1208. <https://doi.org/10.1517/13543776.2015.1056737>
139. D'Arcy P, Wang X, Linder S (2015) Deubiquitinase inhibition as a cancer therapeutic strategy. *Pharmacol Ther* 147:32–54. <https://doi.org/10.1016/j.pharmthera.2014.11.002>

140. Xu GW, Ali M, Wood TE, et al (2010) The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. *Blood* 115:2251–2259. <https://doi.org/10.1182/blood-2009-07-231191>
141. Yang Y, Kitagaki J, Dai R-M, et al (2007) Inhibitors of Ubiquitin-Activating Enzyme (E1), a New Class of Potential Cancer Therapeutics. *Cancer Res* 67:9472–9481. <https://doi.org/10.1158/0008-5472.CAN-07-0568>
142. Hyer ML, Milhollen MA, Ciavarrri J, et al (2018) A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. *Nat Med* 24:186–193. <https://doi.org/10.1038/nm.4474>
143. Barghout SH, Patel PS, Wang X, et al (2019) Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia. *Leukemia* 33:37. <https://doi.org/10.1038/s41375-018-0167-0>
144. Brownell JE, Sintchak MD, Gavin JM, et al (2010) Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ. *Mol Cell* 37:102–111. <https://doi.org/10.1016/j.molcel.2009.12.024>
145. Soucy TA, Smith PG, Milhollen MA, et al (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. *Nature* 458:732–736. <https://doi.org/10.1038/nature07884>
146. Sarantopoulos J, Shapiro GI, Cohen RB, et al (2016) Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. *Clin Cancer Res Off J Am Assoc Cancer Res* 22:847–857. <https://doi.org/10.1158/1078-0432.CCR-15-1338>
147. Shah JJ, Jakubowiak AJ, O'Connor OA, et al (2016) Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. *Clin Cancer Res* 22:34–43. <https://doi.org/10.1158/1078-0432.CCR-15-1237>
148. Bhatia S, Pavlick AC, Boasberg P, et al (2016) A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. *Invest New Drugs* 34:439–449. <https://doi.org/10.1007/s10637-016-0348-5>
149. Nawrocki ST, Kelly KR, Smith PG, et al (2015) The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine. *Clin Cancer Res* 21:439–447. <https://doi.org/10.1158/1078-0432.CCR-14-1960>
150. Visconte V, Nawrocki ST, Espitia CM, et al (2016) Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine. *Leukemia* 30:1190–1194. <https://doi.org/10.1038/leu.2015.250>

151. Swords RT, Coutre S, Maris MB, et al (2018) Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. *Blood* 131:1415–1424. <https://doi.org/10.1182/blood-2017-09-805895>
152. Fukuda I, Ito A, Hirai G, et al (2009) Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. *Chem Biol* 16:133–140. <https://doi.org/10.1016/j.chembiol.2009.01.009>
153. Bossis G, Sarry J-E, Kifagi C, et al (2014) The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs. *Cell Rep* 7:1815–1823. <https://doi.org/10.1016/j.celrep.2014.05.016>
154. Bogachek MV, Park JM, De Andrade JP, et al Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas. *Stem Cell Rep*. <https://doi.org/10.1016/j.stemcr.2016.11.001>
155. Tan J, Chen B, He L, et al (2012) Anacardic acid (6-pentadecylsalicylic acid) induces apoptosis of prostate cancer cells through inhibition of androgen receptor and activation of p53 signaling. *Chin J Cancer Res Chung-Kuo Yen Cheng Yen Chiu* 24:275–283. <https://doi.org/10.3978/j.issn.1000-9604.2012.10.07>
156. Baek SH, Ko J-H, Lee JH, et al (2017) Ginkgolic Acid Inhibits Invasion and Migration and TGF- β -Induced EMT of Lung Cancer Cells Through PI3K/Akt/mTOR Inactivation. *J Cell Physiol* 232:346–354. <https://doi.org/10.1002/jcp.25426>
157. Hamdoun S, Efferth T, Hamdoun S, Efferth T (2017) Ginkgolic acids inhibit migration in breast cancer cells by inhibition of NEMO sumoylation and NF- κ B activity. *Oncotarget* 5:. <https://doi.org/10.18632/oncotarget.16626>
158. Eliseeva ED, Valkov V, Jung M, Jung MO (2007) Characterization of novel inhibitors of histone acetyltransferases. *Mol Cancer Ther* 6:2391–2398. <https://doi.org/10.1158/1535-7163.MCT-07-0159>
159. He X, Riceberg J, Soucy T, et al (2017) Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. *Nat Chem Biol* 13:1164–1171. <https://doi.org/10.1038/nchembio.2463>
160. Pulvino M, Liang Y, Oleksyn D, et al (2012) Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. *Blood* 120:1668–1677. <https://doi.org/10.1182/blood-2012-02-406074>
161. Hodge CD, Edwards RA, Markin CJ, et al (2015) Covalent Inhibition of Ubc13 Affects Ubiquitin Signaling and Reveals Active Site Elements Important for Targeting. *ACS Chem Biol* 10:1718–1728. <https://doi.org/10.1021/acscchembio.5b00222>

162. Strickson S, Campbell DG, Emmerich CH, et al (2013) The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. *Biochem J* 451:427–437. <https://doi.org/10.1042/BJ20121651>
163. Ceccarelli DF, Tang X, Pelletier B, et al (2011) An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme. *Cell* 145:1075–1087. <https://doi.org/10.1016/j.cell.2011.05.039>
164. Huang H, Ceccarelli DF, Orlicky S, et al (2014) E2 enzyme inhibition by stabilization of a low affinity interface with ubiquitin. *Nat Chem Biol* 10:156–163. <https://doi.org/10.1038/nchembio.1412>
165. Sanders MA, Braheimi G, Nangia-Makker P, et al (2013) Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization. *Mol Cancer Ther* 12:373–383. <https://doi.org/10.1158/1535-7163.MCT-12-0793>
166. Sanders MA, Haynes B, Nangia-Makker P, et al (2017) Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs. *J Biol Chem* 292:10347–10363. <https://doi.org/10.1074/jbc.M117.792192>
167. Hirohama M, Kumar A, Fukuda I, et al (2013) Spectomycin B1 as a Novel SUMOylation Inhibitor That Directly Binds to SUMO E2. *ACS Chem Biol*. <https://doi.org/10.1021/cb400630z>
168. Nomura Y, Thuaud F, Sekine D, et al (2019) Synthesis of All Stereoisomers of Monomeric Spectomycin A1/A2 and Evaluation of Their Protein SUMOylation-Inhibitory Activity. *Chem Weinb Bergstr Ger*. <https://doi.org/10.1002/chem.201901093>
169. Kim YS, Nagy K, Keyser S, Schneekloth Jr. JS (2013) An Electrophoretic Mobility Shift Assay Identifies a Mechanistically Unique Inhibitor of Protein Sumoylation. *Chem Biol* 20:604–613. <https://doi.org/10.1016/j.chembiol.2013.04.001>
170. Baik H, Boulanger M, Hosseini M, et al (2018) Targeting the SUMO Pathway Primes All-trans Retinoic Acid-Induced Differentiation of Nonpromyelocytic Acute Myeloid Leukemias. *Cancer Res* 78:2601–2613. <https://doi.org/10.1158/0008-5472.CAN-17-3361>
171. Wertz IE, Wang X (2019) From Discovery to Bedside: Targeting the Ubiquitin System. *Cell Chem Biol* 26:156–177. <https://doi.org/10.1016/j.chembiol.2018.10.022>
172. Gupta A, Shah K, Oza MJ, Behl T (2019) Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. *Biomed Pharmacother* 109:484–492. <https://doi.org/10.1016/j.biopha.2018.10.155>
173. Vassilev LT, Vu BT, Graves B, et al (2004) In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. *Science* 303:844–848. <https://doi.org/10.1126/science.1092472>

174. Ray-Coquard I, Blay J-Y, Italiano A, et al (2012) Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. *Lancet Oncol* 13:1133–1140. [https://doi.org/10.1016/S1470-2045\(12\)70474-6](https://doi.org/10.1016/S1470-2045(12)70474-6)
175. Andreeff M, Kelly KR, Yee K, et al (2016) Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. *Clin Cancer Res* 22:868–876. <https://doi.org/10.1158/1078-0432.CCR-15-0481>
176. Shangary S, Qin D, McEachern D, et al (2008) Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. *Proc Natl Acad Sci* 105:3933–3938. <https://doi.org/10.1073/pnas.0708917105>
177. Sun D, Li Z, Rew Y, et al (2014) Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development. *J Med Chem* 57:1454–1472. <https://doi.org/10.1021/jm401753e>
178. Liao G, Yang D, Ma L, et al (2018) The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy. *Eur J Med Chem* 159:1–9. <https://doi.org/10.1016/j.ejmech.2018.09.044>
179. Klein M (2017) Stabilized helical peptides: overview of the technologies and its impact on drug discovery. *Expert Opin Drug Discov* 1–9. <https://doi.org/10.1080/17460441.2017.1372745>
180. Carvajal LA, Neriah DB, Senecal A, et al (2018) Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. *Sci Transl Med* 10:eaao3003. <https://doi.org/10.1126/scitranslmed.aao3003>
181. Fulda S (2017) Chapter Four - Smac Mimetics to Therapeutically Target IAP Proteins in Cancer. In: Galluzzi L (ed) *International Review of Cell and Molecular Biology*. Academic Press, pp 157–169
182. McComb S, Aguadé-Gorgorió J, Harder L, et al (2016) Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. *Sci Transl Med* 8:339ra70–339ra70. <https://doi.org/10.1126/scitranslmed.aad2986>
183. Carter BZ, Mak PY, Mak DH, et al (2014) Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents. *J Natl Cancer Inst* 106:djt440. <https://doi.org/10.1093/jnci/djt440>
184. Amaravadi RK, Schilder RJ, Martin LP, et al (2015) A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. *Mol Cancer Ther* 14:2569–2575. <https://doi.org/10.1158/1535-7163.MCT-15-0475>
185. Infante JR, Dees EC, Olszanski AJ, et al (2014) Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. *J Clin Oncol* 32:3103–3110. <https://doi.org/10.1200/JCO.2013.52.3993>

186. Saldana M, VanderVorst K, Berg AL, et al (2019) Otubain 1: a non-canonical deubiquitinase with an emerging role in cancer. *Endocr Relat Cancer* 26:R1–R14. <https://doi.org/10.1530/ERC-18-0264>
187. Moore MD, Finnerty B, Gray KD, et al (2018) Decreased UCHL1 expression as a cytologic biomarker for aggressive behavior in pancreatic neuroendocrine tumors. *Surgery* 163:226–231. <https://doi.org/10.1016/j.surg.2017.04.040>
188. Song JS, Yi JM, Cho H, et al (2018) Dual loss of USP10 and p14ARF protein expression is associated with poor prognosis in patients with small intestinal adenocarcinoma. *Tumour Biol J Int Soc Oncodevelopmental Biol Med* 40:1010428318808678. <https://doi.org/10.1177/1010428318808678>
189. Sun J, Li T, Zhao Y, et al (2018) USP10 inhibits lung cancer cell growth and invasion by upregulating PTEN. *Mol Cell Biochem* 441:1–7. <https://doi.org/10.1007/s11010-017-3170-2>
190. Tan Y, Zhou G, Wang X, et al (2018) USP18 promotes breast cancer growth by upregulating EGFR and activating the AKT/Skp2 pathway. *Int J Oncol* 53:371–383. <https://doi.org/10.3892/ijo.2018.4387>
191. Li Y, Yang Y, Li J, et al (2017) USP22 drives colorectal cancer invasion and metastasis via epithelial-mesenchymal transition by activating AP4. *Oncotarget* 8:32683–32695. <https://doi.org/10.18632/oncotarget.15950>
192. Kim D, Hong A, Park HI, et al (2017) Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells. *J Cell Physiol* 232:3664–3676. <https://doi.org/10.1002/jcp.25841>
193. Fang C-L, Lin C-C, Chen H-K, et al (2018) Ubiquitin-specific protease 3 overexpression promotes gastric carcinogenesis and is predictive of poor patient prognosis. *Cancer Sci* 109:3438–3449. <https://doi.org/10.1111/cas.13789>
194. Hu W, Wei H, Li K, et al (2017) Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer. *Cell Prolif* 50:. <https://doi.org/10.1111/cpr.12343>
195. Chen Y, Pang X, Ji L, et al (2018) Reduced Expression of Deubiquitinase USP33 Is Associated with Tumor Progression and Poor Prognosis of Gastric Adenocarcinoma. *Med Sci Monit Int Med J Exp Clin Res* 24:3496–3505. <https://doi.org/10.12659/MSM.908075>
196. Li C, Huang L, Lu H, et al (2018) Expression and clinical significance of ubiquitin- specific- processing protease 34 in diffuse large B- cell lymphoma. *Mol Med Rep* 18:4543–4554. <https://doi.org/10.3892/mmr.2018.9447>
197. Qin T, Li B, Feng X, et al (2018) Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity. *J Exp Clin Cancer Res CR* 37:287. <https://doi.org/10.1186/s13046-018-0934-9>

198. Xu Y, Zhu M-R, Zhang J-Y, et al (2018) Knockdown of ubiquitin- specific peptidase 39 inhibits the malignant progression of human renal cell carcinoma. *Mol Med Rep* 17:4729–4735. <https://doi.org/10.3892/mmr.2018.8421>
199. Fraile JM, Manchado E, Lujambio A, et al (2017) USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. *J Biol Chem* 292:4164–4175. <https://doi.org/10.1074/jbc.M116.762757>
200. Yuan X, Sun X, Shi X, et al (2017) USP39 promotes colorectal cancer growth and metastasis through the Wnt/ β -catenin pathway. *Oncol Rep* 37:2398–2404. <https://doi.org/10.3892/or.2017.5454>
201. Guo W, Ma J, Pei T, et al (2018) Up-regulated deubiquitinase USP4 plays an oncogenic role in melanoma. *J Cell Mol Med* 22:2944–2954. <https://doi.org/10.1111/jcmm.13603>
202. Luo K, Li Y, Yin Y, et al (2017) USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling. *EMBO J* 36:1434–1446. <https://doi.org/10.15252/embj.201695669>
203. Li X-Y, Wu H-Y, Mao X-F, et al (2017) USP5 promotes tumorigenesis and progression of pancreatic cancer by stabilizing FoxM1 protein. *Biochem Biophys Res Commun* 492:48–54. <https://doi.org/10.1016/j.bbrc.2017.08.040>
204. Zhan M, Sun X, Liu J, et al (2017) Usp7 promotes medulloblastoma cell survival and metastasis by activating Shh pathway. *Biochem Biophys Res Commun* 484:429–434. <https://doi.org/10.1016/j.bbrc.2017.01.144>
205. Zeng Q, Li Z, Zhao X, et al (2019) Ubiquitin- specific protease 7 promotes osteosarcoma cell metastasis by inducing epithelial- mesenchymal transition. *Oncol Rep* 41:543–551. <https://doi.org/10.3892/or.2018.6835>
206. Yan M, Zhao C, Wei N, et al (2018) High Expression of Ubiquitin-Specific Protease 8 (USP8) Is Associated with Poor Prognosis in Patients with Cervical Squamous Cell Carcinoma. *Med Sci Monit Int Med J Exp Clin Res* 24:4934–4943. <https://doi.org/10.12659/MSM.909235>
207. Liu L, Yao D, Zhang P, et al (2017) Deubiquitinase USP9X promotes cell migration, invasion and inhibits apoptosis of human pancreatic cancer. *Oncol Rep* 38:3531–3537. <https://doi.org/10.3892/or.2017.6050>
208. Li X, Song N, Liu L, et al (2017) USP9X regulates centrosome duplication and promotes breast carcinogenesis. *Nat Commun* 8:14866. <https://doi.org/10.1038/ncomms14866>
209. Zhou C, Bi F, Yuan J, et al (2018) Gain of UBE2D1 facilitates hepatocellular carcinoma progression and is associated with DNA damage caused by continuous IL-6. *J Exp Clin Cancer Res CR* 37:290. <https://doi.org/10.1186/s13046-018-0951-8>

210. Ma X, Zhao J, Yang F, et al (2017) Ubiquitin conjugating enzyme E2 L3 promoted tumor growth of NSCLC through accelerating p27kip1 ubiquitination and degradation. *Oncotarget* 8:84193–84203. <https://doi.org/10.18632/oncotarget.20449>
211. Pan Y-H, Yang M, Liu L-P, et al (2018) UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma. *Biochem Biophys Res Commun* 503:895–902. <https://doi.org/10.1016/j.bbrc.2018.06.093>
212. Liu L-P, Yang M, Peng Q-Z, et al (2017) UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53. *Biochem Biophys Res Commun* 493:20–27. <https://doi.org/10.1016/j.bbrc.2017.09.091>
213. Luo C, Yao Y, Yu Z, et al (2017) UBE2T knockdown inhibits gastric cancer progression. *Oncotarget* 8:32639–32654. <https://doi.org/10.18632/oncotarget.15947>
214. Vila IK, Yao Y, Kim G, et al (2017) A UBE2O-AMPK α 2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy. *Cancer Cell* 31:208–224. <https://doi.org/10.1016/j.ccell.2017.01.003>
215. Ullah K, Zubia E, Narayan M, et al (2018) Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset. *FEBS J*. <https://doi.org/10.1111/febs.14708>
216. Jiang X, Li C, Lin B, et al (2017) cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF- κ B pathway. *Cancer Sci* 108:1144–1156. <https://doi.org/10.1111/cas.13236>
217. Dornan D, Bheddah S, Newton K, et al (2004) COP1, the Negative Regulator of p53, Is Overexpressed in Breast and Ovarian Adenocarcinomas. *Cancer Res* 64:7226–7230. <https://doi.org/10.1158/0008-5472.CAN-04-2601>
218. Marine J-C (2012) Spotlight on the role of COP1 in tumorigenesis. *Nat Rev Cancer* 12:455–464. <https://doi.org/10.1038/nrc3271>
219. Michail O, Moris D, Theocharis S, Griniatsos J (2018) Cullin-1 and -2 Protein Expression in Colorectal Cancer: Correlation with Clinicopathological Variables. *Vivo Athens Greece* 32:391–396. <https://doi.org/10.21873/invivo.11251>
220. Zeng R, Tan G, Li W, Ma Y (2018) Increased Expression of Cullin 3 in Nasopharyngeal Carcinoma and Knockdown Inhibits Proliferation and Invasion. *Oncol Res* 26:111–122. <https://doi.org/10.3727/096504017X14924753593574>
221. Raghu D, Paul PJ, Gulati T, et al (2017) E6AP promotes prostate cancer by reducing p27 expression. *Oncotarget* 8:42939–42948. <https://doi.org/10.18632/oncotarget.17224>
222. Paul PJ, Raghu D, Chan A-L, et al (2016) Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. *Oncogene* 35:6235–6245. <https://doi.org/10.1038/onc.2016.159>

223. Gamell C, Gulati T, Levav-Cohen Y, et al (2017) Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer. *Sci Signal* 10:eaaf8223. <https://doi.org/10.1126/scisignal.aaf8223>
224. Sun C, Tao Y, Gao Y, et al (2018) F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT. *Biomed Pharmacother Biomedecine Pharmacother* 98:416–423. <https://doi.org/10.1016/j.biopha.2017.12.088>
225. Khan M, Muzumdar D, Shiras A (2019) Attenuation of Tumor Suppressive Function of FBXO16 Ubiquitin Ligase Activates Wnt Signaling In Glioblastoma. *Neoplasia N Y N* 21:106–116. <https://doi.org/10.1016/j.neo.2018.11.005>
226. Suber TL, Nikolli I, O'Brien ME, et al (2018) FBXO17 promotes cell proliferation through activation of Akt in lung adenocarcinoma cells. *Respir Res* 19:206. <https://doi.org/10.1186/s12931-018-0910-0>
227. Zou S, Ma C, Yang F, et al (2018) FBXO31 Suppresses Gastric Cancer EMT by Targeting Snail1 for Proteasomal Degradation. *Mol Cancer Res MCR* 16:286–295. <https://doi.org/10.1158/1541-7786.MCR-17-0432>
228. Zhou H, Liu Y, Zhu R, et al (2017) FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation. *Oncogene* 36:3312–3321. <https://doi.org/10.1038/onc.2016.479>
229. Yeh C-H, Bellon M, Nicot C (2018) FBXW7: a critical tumor suppressor of human cancers. *Mol Cancer* 17:115. <https://doi.org/10.1186/s12943-018-0857-2>
230. Kao S-H, Wu H-T, Wu K-J (2018) Ubiquitination by HUWE1 in tumorigenesis and beyond. *J Biomed Sci* 25:67. <https://doi.org/10.1186/s12929-018-0470-0>
231. Sampath D, Calin GA, Puduvalli VK, et al (2009) Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. *Blood* 113:3744–3753. <https://doi.org/10.1182/blood-2008-09-178707>
232. Salah Z, Melino G, Aqeilan RI (2011) Negative Regulation of the Hippo Pathway by E3 Ubiquitin Ligase ITCH Is Sufficient to Promote Tumorigenicity. *Cancer Res* 71:2010–2020. <https://doi.org/10.1158/0008-5472.CAN-10-3516>
233. Salah Z, Itzhaki E, Aqeilan RI (2014) The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway. *Oncotarget* 5:10886–10900. <https://doi.org/10.18632/oncotarget.2540>
234. Li P-F, Zhang Q-G (2018) Inhibition of ITCH Suppresses Proliferation and Induces Apoptosis of Lung Cancer Cells. *Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol* 48:1703–1709. <https://doi.org/10.1159/000492295>

235. Steklov M, Pandolfi S, Baietti MF, et al (2018) Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination. *Science* 362:1177–1182. <https://doi.org/10.1126/science.aap7607>
236. Mayo LD, Dixon JE, Durden DL, et al (2002) PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy. *J Biol Chem* 277:5484–5489. <https://doi.org/10.1074/jbc.M108302200>
237. Wade M, Li Y-C, Wahl GM (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. *Nat Rev Cancer* 13:83–96. <https://doi.org/10.1038/nrc3430>
238. Laurie NA, Donovan SL, Shih C-S, et al (2006) Inactivation of the p53 pathway in retinoblastoma. *Nature* 444:61. <https://doi.org/10.1038/nature05194>
239. Shao G, Wang R, Sun A, et al (2018) The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells. *Mol Cancer* 17:24. <https://doi.org/10.1186/s12943-018-0784-2>
240. Wen W, Li J, Wang L, et al (2017) Inhibition of NEDD4 inhibits cell growth and invasion and induces cell apoptosis in bladder cancer cells. *Cell Cycle Georget Tex* 16:1509–1514. <https://doi.org/10.1080/15384101.2017.1338220>
241. Weng M, Luo Z-L, Wu X-L, Zeng W-Z (2017) The E3 ubiquitin ligase NEDD4 is translationally upregulated and facilitates pancreatic cancer. *Oncotarget* 8:20288–20296. <https://doi.org/10.18632/oncotarget.15446>
242. Eide PW, Cekaite L, Danielsen SA, et al (2013) NEDD4 is overexpressed in colorectal cancer and promotes colonic cell growth independently of the PI3K/PTEN/AKT pathway. *Cell Signal* 25:12–18. <https://doi.org/10.1016/j.cellsig.2012.08.012>
243. Kito Y, Bai J, Goto N, et al (2014) Pathobiological properties of the ubiquitin ligase Nedd4L in melanoma. *Int J Exp Pathol* 95:24–28. <https://doi.org/10.1111/iep.12051>
244. Qu M-H, Han C, Srivastava AK, et al (2016) miR-93 promotes TGF- β -induced epithelial-to-mesenchymal transition through downregulation of NEDD4L in lung cancer cells. *Tumour Biol J Int Soc Oncodevelopmental Biol Med* 37:5645–5651. <https://doi.org/10.1007/s13277-015-4328-8>
245. Tanksley JP, Chen X, Coffey RJ (2013) NEDD4L is downregulated in colorectal cancer and inhibits canonical WNT signaling. *PloS One* 8:e81514. <https://doi.org/10.1371/journal.pone.0081514>
246. Zhao R, Cui T, Han C, et al (2015) DDB2 modulates TGF- β signal transduction in human ovarian cancer cells by downregulating NEDD4L. *Nucleic Acids Res* 43:7838–7849. <https://doi.org/10.1093/nar/gkv667>

247. Hu XY, Xu YM, Fu Q, et al (2009) Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia. *Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol* 35:527–531. <https://doi.org/10.1016/j.ejso.2008.09.015>
248. Bao Y, Wu X, Yuan D, et al (2017) High Expression of Pirh2 is Associated with Poor Prognosis in Glioma. *Cell Mol Neurobiol* 37:1501–1509. <https://doi.org/10.1007/s10571-017-0481-5>
249. Logan IR, Gaughan L, McCracken SRC, et al (2006) Human PIRH2 Enhances Androgen Receptor Signaling through Inhibition of Histone Deacetylase 1 and Is Overexpressed in Prostate Cancer. *Mol Cell Biol* 26:6502–6510. <https://doi.org/10.1128/MCB.00147-06>
250. Shimada M, Kitagawa K, Dobashi Y, et al (2009) High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers. *Cancer Sci* 100:866–872
251. Duan W, Gao L, Druhan LJ, et al (2004) Expression of Pirh2, a Newly Identified Ubiquitin Protein Ligase, in Lung Cancer. *JNCI J Natl Cancer Inst* 96:1718–1721. <https://doi.org/10.1093/jnci/djh292>
252. Wang X-M, Yang L-Y, Guo L, et al (2009) p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. *Cancer* 115:4554–4563. <https://doi.org/10.1002/cncr.24494>
253. Wu H, Li X, Feng M, et al (2018) Downregulation of RNF138 inhibits cellular proliferation, migration, invasion and EMT in glioma cells via suppression of the Erk signaling pathway. *Oncol Rep* 40:3285–3296. <https://doi.org/10.3892/or.2018.6744>
254. Shen J, Yu Z, Li N (2018) The E3 ubiquitin ligase RNF146 promotes colorectal cancer by activating the Wnt/ β -catenin pathway via ubiquitination of Axin1. *Biochem Biophys Res Commun* 503:991–997. <https://doi.org/10.1016/j.bbrc.2018.06.107>
255. Qiu D, Wang Q, Wang Z, et al (2018) RNF185 modulates JWA ubiquitination and promotes gastric cancer metastasis. *Biochim Biophys Acta Mol Basis Dis* 1864:1552–1561. <https://doi.org/10.1016/j.bbadis.2018.02.013>
256. Sethi G, Shanmugam MK, Arfuso F, Kumar AP (2018) Role of RNF20 in cancer development and progression – a comprehensive review. *Biosci Rep* 38:BSR20171287. <https://doi.org/10.1042/BSR20171287>
257. Gao Y, Cai A, Xi H, et al (2017) Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt- β /catenin signaling pathway. *Stem Cell Res Ther* 8:98. <https://doi.org/10.1186/s13287-017-0548-8>
258. Xiao Y, Jiang Y, Song H, et al (2017) RNF7 knockdown inhibits prostate cancer tumorigenesis by inactivation of ERK1/2 pathway. *Sci Rep* 7:43683. <https://doi.org/10.1038/srep43683>

259. Gopalsamy A, Hagen T, Swaminathan K (2014) Investigating the Molecular Basis of Siah1 and Siah2 E3 Ubiquitin Ligase Substrate Specificity. *PLOS ONE* 9:e106547. <https://doi.org/10.1371/journal.pone.0106547>
260. Jiang X, Shen X (2018) Knockdown of miR-299-5p inhibits the progression of hepatocellular carcinoma by targeting SIAH1. *Bull Cancer (Paris)* 105:873–883. <https://doi.org/10.1016/j.bulcan.2018.07.013>
261. Hung W-C, Tseng W-L, Shiea J, Chang H-C (2010) Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. *Cancer Lett* 288:156–161. <https://doi.org/10.1016/j.canlet.2009.06.032>
262. Lee S-W, Li C-F, Jin G, et al (2015) Skp2-Dependent Ubiquitination and Activation of LKB1 Is Essential for Cancer Cell Survival under Energy Stress. *Mol Cell* 57:1022–1033. <https://doi.org/10.1016/j.molcel.2015.01.015>
263. Tosco P, La Terra Maggiore GM, Forni P, et al (2011) Correlation between Skp2 expression and nodal metastasis in stage I and II oral squamous cell carcinomas. *Oral Dis* 17:102–108. <https://doi.org/10.1111/j.1601-0825.2010.01713.x>
264. Saigusa K, Hashimoto N, Tsuda H, et al (2005) Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas. *Cancer Sci* 96:676–683. <https://doi.org/10.1111/j.1349-7006.2005.00099.x>
265. Loukopoulos P, Shibata T, Katoh H, et al (2007) Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: Identification of genetic indicators that predict patient outcome. *Cancer Sci* 98:392–400. <https://doi.org/10.1111/j.1349-7006.2007.00395.x>
266. Tao Y, Sun C, Zhang T, Song Y (2017) SMURF1 promotes the proliferation, migration and invasion of gastric cancer cells. *Oncol Rep* 38:1806–1814. <https://doi.org/10.3892/or.2017.5825>
267. Yan C, Su H, Song X, et al (2018) Smad Ubiquitination Regulatory Factor 1 (Smurf1) Promotes Thyroid Cancer Cell Proliferation and Migration via Ubiquitin-Dependent Degradation of Kisspeptin-1. *Cell Physiol Biochem* 49:2047–2059. <https://doi.org/10.1159/000493715>
268. Chang H, Zhang J, Miao Z, et al (2018) Suppression of the Smurf1 Expression Inhibits Tumor Progression in Gliomas. *Cell Mol Neurobiol* 38:421–430. <https://doi.org/10.1007/s10571-017-0485-1>
269. Wang W, Du H, Liu H, et al (2019) SMAD specific E3 ubiquitin protein ligase 1 promotes ovarian cancer cell migration and invasion via the activation of the RhoA/ROCK signaling pathway. *Oncol Rep* 41:668–676. <https://doi.org/10.3892/or.2018.6836>

270. Fukuchi M, Fukai Y, Masuda N, et al (2002) High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. *Cancer Res* 62:7162–7165
271. Jin C, Yang Y, Anver MR, et al (2009) Smad Ubiquitination Regulatory Factor 2 Promotes Metastasis of Breast Cancer Cells by Enhancing Migration and Invasiveness. *Cancer Res* 69:735–740. <https://doi.org/10.1158/0008-5472.CAN-08-1463>
272. Fukasawa H, Yamamoto T, Fujigaki Y, et al (2010) Reduction of transforming growth factor- β type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma. *Int J Cancer* 127:1517–1525. <https://doi.org/10.1002/ijc.25164>
273. Chen Y, Li L, Qian X, et al (2017) High expression of TRIM11 correlates with poor prognosis in patients with hepatocellular carcinoma. *Clin Res Hepatol Gastroenterol* 41:190–196. <https://doi.org/10.1016/j.clinre.2016.09.010>
274. Zhang Z, Xu C, Zhang X, et al (2017) TRIM11 Upregulation Contributes to Proliferation, Invasion, and EMT of Hepatocellular Carcinoma Cells. *Oncol Res* 25:691–699. <https://doi.org/10.3727/096504016X14774897404770>
275. Pan Y, Zhang R, Chen H, et al (2019) Expression of Tripartite Motif-Containing Proteactiin 11 (TRIM11) is Associated with the Progression of Human Prostate Cancer and is Downregulated by MicroRNA-5193. *Med Sci Monit Int Med J Exp Clin Res* 25:98–106. <https://doi.org/10.12659/MSM.911818>
276. Qin X, Qiu F, Zou Z (2017) TRIM25 is associated with cisplatin resistance in non-small-cell lung carcinoma A549 cell line via downregulation of 14-3-3 σ . *Biochem Biophys Res Commun* 493:568–572. <https://doi.org/10.1016/j.bbrc.2017.08.151>
277. Sun N, Xue Y, Dai T, et al (2017) Tripartite motif containing 25 promotes proliferation and invasion of colorectal cancer cells through TGF- β signaling. *Biosci Rep* 37:. <https://doi.org/10.1042/BSR20170805>
278. Takayama K-I, Suzuki T, Tanaka T, et al (2018) TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer. *Oncogene* 37:2165–2180. <https://doi.org/10.1038/s41388-017-0095-x>
279. Zang H-L, Ren S-N, Cao H, Tian X-F (2017) The ubiquitin ligase TRIM25 inhibits hepatocellular carcinoma progression by targeting metastasis associated 1 protein. *IUBMB Life* 69:795–801. <https://doi.org/10.1002/iub.1661>
280. Fong K, Zhao JC, Song B, et al (2018) TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression. *Nat Commun* 9:5007. <https://doi.org/10.1038/s41467-018-07475-5>
281. Li H, Zhang Y, Hai J, et al (2018) Knockdown of TRIM31 suppresses proliferation and invasion of gallbladder cancer cells by down-regulating MMP2/9 through the PI3K/Akt

signaling pathway. *Biomed Pharmacother Biomedecine Pharmacother* 103:1272–1278. <https://doi.org/10.1016/j.biopha.2018.04.120>

282. Guo P, Ma X, Zhao W, et al (2018) TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex. *Oncogene* 37:478–488. <https://doi.org/10.1038/onc.2017.349>
283. Zhang J, Zhang C, Cui J, et al (2017) TRIM45 functions as a tumor suppressor in the brain via its E3 ligase activity by stabilizing p53 through K63-linked ubiquitination. *Cell Death Dis* 8:e2831. <https://doi.org/10.1038/cddis.2017.149>
284. Chen Y, Zhao J, Li D, et al (2018) TRIM56 Suppresses Multiple Myeloma Progression by Activating TLR3/TRIF Signaling. *Yonsei Med J* 59:43–50. <https://doi.org/10.3349/ymj.2018.59.1.43>
285. Zhao L, Zhang P, Su X-J, Zhang B (2018) The ubiquitin ligase TRIM56 inhibits ovarian cancer progression by targeting vimentin. *J Cell Physiol* 233:2420–2425. <https://doi.org/10.1002/jcp.26114>
286. Liao L, Song M, Li X, et al (2017) E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer. *Cancer Res* 77:2090–2101. <https://doi.org/10.1158/0008-5472.CAN-16-2409>
287. Chen C, Sun X, Guo P, et al (2007) Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. *Oncogene* 26:2386–2394. <https://doi.org/10.1038/sj.onc.1210021>
288. Chen C, Zhou Z, Ross JS, et al (2007) The amplified WWP1 gene is a potential molecular target in breast cancer. *Int J Cancer* 121:80–87. <https://doi.org/10.1002/ijc.22653>
289. Sanarico AG, Ronchini C, Croce A, et al (2018) The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia. *Leukemia* 32:911–919. <https://doi.org/10.1038/leu.2017.342>
290. Wu Z, Zan P, Li S, et al (2015) Knockdown of WWP1 inhibits growth and invasion, but induces apoptosis of osteosarcoma cells. *Int J Clin Exp Pathol* 8:7869–7877
291. Zhang L, Wu Z, Ma Z, et al (2015) WWP1 as a potential tumor oncogene regulates PTEN-Akt signaling pathway in human gastric carcinoma. *Tumor Biol* 36:787–798. <https://doi.org/10.1007/s13277-014-2696-0>
292. Yang R, He Y, Chen S, et al (2016) Elevated expression of WWP2 in human lung adenocarcinoma and its effect on migration and invasion. *Biochem Biophys Res Commun* 479:146–151. <https://doi.org/10.1016/j.bbrc.2016.07.084>
293. Liang J, Qi W-F, Xie S, et al (2017) Expression of WW domain-containing protein 2 is correlated with pathological grade and recurrence of glioma. *J Cancer Res Ther* 13:1032–1037. <https://doi.org/10.4103/0973-1482.176176>

294. Liu K, Zhang J, Wang H (2018) Small ubiquitin-like modifier/sentrin-specific peptidase 1 associates with chemotherapy and is a risk factor for poor prognosis of non-small cell lung cancer. *J Clin Lab Anal* 32:e22611. <https://doi.org/10.1002/jcla.22611>
295. Zhou G-Q, Han F, Shi Z-L, et al (2018) miR-133a-3p Targets SUMO-Specific Protease 1 to Inhibit Cell Proliferation and Cell Cycle Progress in Colorectal Cancer. *Oncol Res* 26:795–800. <https://doi.org/10.3727/096504017X15004613574679>
296. Dong B, Gao Y, Kang X, et al (2016) SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis. *Oncotarget* 7:80435–80449. <https://doi.org/10.18632/oncotarget.12606>
297. Zhang W, Sun H, Shi X, et al (2016) SENP1 regulates hepatocyte growth factor-induced migration and epithelial-mesenchymal transition of hepatocellular carcinoma. *Tumour Biol J Int Soc Oncodevelopmental Biol Med* 37:7741–7748. <https://doi.org/10.1007/s13277-015-4406-y>
298. Bawa-Khalfe T, Yang F-M, Ritho J, et al (2017) SENP1 regulates PTEN stability to dictate prostate cancer development. *Oncotarget* 8:17651–17664. <https://doi.org/10.18632/oncotarget.13283>
299. Wu J, Lei H, Zhang J, et al (2016) Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation. *Oncotarget* 7:58995–59005. <https://doi.org/10.18632/oncotarget.10636>
300. Sun X-X, Chen Y, Su Y, et al (2018) SUMO protease SENP1 deSUMOylates and stabilizes c-Myc. *Proc Natl Acad Sci U S A* 115:10983–10988. <https://doi.org/10.1073/pnas.1802932115>
301. Wang Z, Jin J, Zhang J, et al (2016) Depletion of SENP1 suppresses the proliferation and invasion of triple-negative breast cancer cells. *Oncol Rep* 36:2071–2078. <https://doi.org/10.3892/or.2016.5036>
302. Xia W, Tian H, Cai X, et al (2016) Inhibition of SUMO-specific protease 1 induces apoptosis of astrogloma cells by regulating NF- κ B/Akt pathways. *Gene* 595:175–179. <https://doi.org/10.1016/j.gene.2016.09.040>
303. Wang X, Liang X, Liang H, Wang B (2018) SENP1/HIF-1 α feedback loop modulates hypoxia-induced cell proliferation, invasion, and EMT in human osteosarcoma cells. *J Cell Biochem* 119:1819–1826. <https://doi.org/10.1002/jcb.26342>
304. Liu F, Li L, Li Y, et al (2018) Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV. *Int J Oncol* 53:2010–2020. <https://doi.org/10.3892/ijo.2018.4537>
305. Tan M, Zhang D, Zhang E, et al (2017) SENP2 suppresses epithelial-mesenchymal transition of bladder cancer cells through deSUMOylation of TGF- β RI. *Mol Carcinog* 56:2332–2341. <https://doi.org/10.1002/mc.22687>

306. Hu X-Y, Liu Z, Zhang K-L, et al (2017) SUMO-specific protease 2-mediated deSUMOylation is required for NDRG2 stabilization in gastric cancer cells. *Cancer Biomark Sect Dis Markers* 21:195–201. <https://doi.org/10.3233/CBM-170651>
307. Chen X-L, Wang S-F, Liang X-T, et al (2019) SENP2 exerts an anti- tumor effect on chronic lymphocytic leukemia cells through the inhibition of the Notch and NF- κ B signaling pathways. *Int J Oncol* 54:455–466. <https://doi.org/10.3892/ijo.2018.4635>
308. Cheng J, Su M, Jin Y, et al (2017) Upregulation of SENP3/SMT3IP1 promotes epithelial ovarian cancer progression and forecasts poor prognosis. *Tumour Biol J Int Soc Oncodevelopmental Biol Med* 39:1010428317694543. <https://doi.org/10.1177/1010428317694543>
309. Jin Z-L, Pei H, Xu Y-H, et al (2016) The SUMO-specific protease SENP5 controls DNA damage response and promotes tumorigenesis in hepatocellular carcinoma. *Eur Rev Med Pharmacol Sci* 20:3566–3573
310. Cerami E, Gao J, Dogrusoz U, et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2:401–404. <https://doi.org/10.1158/2159-8290.CD-12-0095>
311. Li J, Sun X, He P, et al (2018) Ubiquitin-like modifier activating enzyme 2 promotes cell migration and invasion through Wnt/ β -catenin signaling in gastric cancer. *World J Gastroenterol* 24:4773–4786. <https://doi.org/10.3748/wjg.v24.i42.4773>
312. Fang S, Qiu J, Wu Z, et al (2017) Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin. *Oncotarget* 8:49783–49795. <https://doi.org/10.18632/oncotarget.17939>
313. Zhang D, Yu K, Yang Z, et al (2018) Silencing Ubc9 expression suppresses osteosarcoma tumorigenesis and enhances chemosensitivity to HSV-TK/GCV by regulating connexin 43 SUMOylation. *Int J Oncol* 53:1323–1331. <https://doi.org/10.3892/ijo.2018.4448>
314. Chanda A, Chan A, Deng L, et al (2017) Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer. *PloS One* 12:e0177639. <https://doi.org/10.1371/journal.pone.0177639>
315. Hoefer J, Schäfer G, Klocker H, et al (2012) PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. *Am J Pathol* 180:2097–2107. <https://doi.org/10.1016/j.ajpath.2012.01.026>
316. Pühr M, Hoefer J, Eigentler A, et al (2016) PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. *Oncogene* 35:2322–2332. <https://doi.org/10.1038/onc.2015.292>
317. Driscoll JJ, Pelluru D, Lefkimmatis K, et al (2010) The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. *Blood* 115:2827–2834. <https://doi.org/10.1182/blood-2009-03-211045>

318. Guo Z, Wang Y, Zhao Y, et al (2019) The pivotal oncogenic role of Jab1/CSN5 and its therapeutic implications in human cancer. *Gene* 687:219–227. <https://doi.org/10.1016/j.gene.2018.11.061>
319. Lee G-W, Park JB, Park SY, et al (2018) The E3 ligase C-CBL inhibits cancer cell migration by neddylation of the proto-oncogene c-Src. *Oncogene* 37:5552–5568. <https://doi.org/10.1038/s41388-018-0354-5>

Modifier	Homology with ubiquitin	E1	E2	E3	Protease	Functions
Ubiquitin	100	UBE1, UBA6	38	>600	~100	Multiples, proteasomal degradation
SUMO1-5	15	SAE1/SAE2	UBC9	>15	~10	Protein/protein interaction, regulation of transcription
NEDD8	58	NAE1/UBA3	UBC12, UBE2F	>10	CSN5, NEDP1	Cullins activation, cell cycle
ISG15	27	UBE1L	UBCH8	HERC5, EFP, HHARI	USP18	Immune response, response to stress
FUB1	36					Unknown, immune response regulation
FAT10	27	UBA6	USE2		0	Proteasomal degradation
URM1	17	UBA4				tRNA thiolation, oxydative stress response
UBL5	25					RNA splicing, cell polarisation
UFM1	23	UBA5	UFC1	UFL1	UFSP1, UFSP2	Hematopoiesis, NF-κB regulation
ATG8		ATG7	ATG3		ATG4	Autophagy
ATG12	12	ATG7	ATG10		0	Autophagy
MAP1LC3A	9	ATG7	ATG3	ATG12, ATG5, ATG16L	ATG4A, ATG4B, ATG4C, ATG4D	Autophagosomes formation
MAP1LC3B	13					
MAP1LC3C	10					
GABARAP	8					
GABARAPL1	12					
GABARAPL2	14					
GABARAPL3						

Table 1: Ubiquitin-like modifiers: conjugation/deconjugation enzymes and main functions

UbL	Enzyme	Enzyme	Dysregulation	Cancer	Reference
Ub	DUB	OTUB1	Overexpression	lung, breast, ovarian, glioma, colon, gastric	[186]
		UCHL1	Underexpression	pancreatic	[187]
		USP10	Underexpression	small intestinal adenocarcinoma	[188]
		USP10	Underexpression	lung	[189]
		USP18	Overexpression	breast	[190]
		USP22	Overexpression	Colorectal, breast	[191, 192]
		USP3	Overexpression	gastric	[193]
		USP32	Overexpression	SCL	[194]
		USP33	Underexpression	gastric	[195]
		USP34	Overexpression	Diffuse large B-cell lymphoma	[196]
		USP37	Overexpression	Breast	[197]
		USP39	Overexpression	Renal, colorectal, lung	[198–200]
		USP4	Overexpression	melanoma	[201]
		USP49	Underexpression	pancreatic	[202]
		USP5	Overexpression	Pancreatic	[203]
		USP7	Overexpression	Osteosarcoma, medulloblastoma	[204, 205]
		USP8	Overexpression	cervical	[206]
		USP9X	Overexpression	Pancreatic, breast	[207, 208]
	E2	UBE2D1	Overexpression	Hepatocellular carcinoma	[209]
		UBE2L3	Overexpression	NSCL	[210]
		UBE2S	Overexpression	Hepatocellular	[211]
		UBE2T	Overexpression	Hepatocellular, gastric	[212, 213]
	E2/E3	UBE2O	Overexpression/mutation	Gastric, lung, breast, prostate, colorectal, TNBC	[214, 215]
	E3	ciAP2	Overexpression	Gallbladder	[216]
		COP1	Overexpression	Breast, ovarian, leukemia, melanoma, lung	[217, 218]
		CUL-1	Overexpression	colorectal	[219]
		CUL-2	Overexpression	colorectal	[219]
		CUL-3	Overexpression	nasopharyngeal	[220]

		E6AP	Overexpression	Prostate, NSCL	[221–223]
		FBX011	Overexpression	gastric	[224]
		FBX016	Underexpression	Glioblastoma	[225]
		FBX017	Overexpression	lung	[226]
		FBX031	Underexpression	gastric	[227]
		FBX032	Underexpression	breast	[228]
		FBXW7	Underexpression	Acute lymphoblastic leukemia, colorectal, esophageal, gastric, hepatocellular, NSCL, breast	[229]
		HUWE1	Overexpression	Breast, lung, prostate, larynx, stomach, uterus	[230]
			Underexpression	brain	
		ITCH	Overexpression	Lung, CLL, breast	[231–234]
		LZTR1	Mutation	RAS-driven cancers	[235]
		MDM2	Overexpression	Retinoblastoma, glioblastoma, colorectal, melanoma, breast	[236–238]
		NEDD4	Overexpression	Lung, bladder, pancreatic, colorectal	[239–242]
		NEDD4L	Underexpression	Colorectal, pancreatic, melanoma, lung, ovarian, prostate	[243–247]
		Pirh2	Overexpression	Glioma, head and neck, prostate, lung, hepatocellular	[248–252]
		RNF138	Overexpression	glioma	[253]
		RNF146	Overexpression	colorectal	[254]
		RNF185	Overexpression	gastric	[255]
		RNF20	Underexpression	breast, lung, prostate cancer, clear cell renal cell carcinoma, mixed lineage	[256]

				leukemia	
		RNF43	Underexpression	gastric	[257]
		RNF7	Overexpression	prostate	[258]
		SIAH1	Underexpression	Hepatocellular carcinoma, gastric	[259, 260]
		SIAH2	Overexpression	Breast, lung, pancreatic, prostate, liver, melanoma	[259]
		SKP2	Overexpression	Hepatocellular, lung, oral squamous cell, glioblastoma	[261–264]
		SMURF1	Overexpression	Ovarian, thyroid, gastric, glioma, pancreatic	[265–269]
		SMURF2	Overexpression	Renal, breast, esophageal	[270–272]
		TRIM11	Overexpression	Prostate, hepatocellular	[273–275]
		TRIM25	Overexpression	Prostate, NSCL, colorectal	[276–278]
			Underexpression	hepatocellular	[279]
		TRIM28	Overexpression	Prostate	[280]
		TRIM31	Overexpression	Gallbladder, hepatocellular	[281, 282]
		TRIM45	Underexpression	glioblastoma	[283]
		TRIM56	Underexpression	Multiple myeloma, ovarian	[284, 285]
		UBR5	Overexpression	TNBC	[286]
		WWP1	Overexpression	AML, prostate, breast, gastric, osteosarcoma	[287–291]
		WWP2	Overexpression	Glioma, lung adenocarcinoma	[292, 293]
		XIAP	Overexpression	Breast, colon	[119]
SUMO	DUB	SENP1	Overexpression	NSCL, colorectal, renal, hepatocellular, prostate, breast, astrogloma	[294–302]
			Underexpression	osteosarcoma	[303, 304]
		SENP2	Underexpression	Bladder, gastric,	[305–307]

				chronic lymphocytic leukemia	
		SENP3	Overexpression	ovarian	[308]
		SENP5	Overexpression	hepatocellular	[309]
	E1	SAE1/2	Overexpression	Gastric, colorectal, breast, prostate, pancreatic, hepatocellular	[131, 310, 311]
	E2	UBC9	Overexpression	Breast, prostate, pancreatic, osteosarcoma, hepatocellular	[310, 312, 313]
	E3	PIAS1	Underexpression	breast	[314]
			Overexpression	Prostate, multiple myeloma	[315–317]
		PIAS3	Overexpression	colorectal	[310]
NEDD8	DUB	Jab1/CSN 5	Overexpression	Breast, ovarian, hepatocellular, NSCLC, Oral squamous cell, Laryngeal, thyroid, pancreatic, esophageal, colorectal, gastric	[318]
	E3	C-CBL	Underexpression	lung	[319]

Table 2: Dysregulation of UbL enzymes in cancer. This table summarizes the known dysregulations of these enzymes. It comprises the main enzymes in each pathway but is not necessarily exhaustive.

Figure 1: Regulation of p53 by UbL. N8: Nedd8, Ub: Ubiquitin, S: SUMO